WO2018231752A1 - Sting-dependent activators for treatment of disease - Google Patents
Sting-dependent activators for treatment of disease Download PDFInfo
- Publication number
- WO2018231752A1 WO2018231752A1 PCT/US2018/036997 US2018036997W WO2018231752A1 WO 2018231752 A1 WO2018231752 A1 WO 2018231752A1 US 2018036997 W US2018036997 W US 2018036997W WO 2018231752 A1 WO2018231752 A1 WO 2018231752A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sting
- activator
- cells
- modified
- nucleotides
- Prior art date
Links
- 239000012190 activator Substances 0.000 title claims abstract description 81
- 238000011282 treatment Methods 0.000 title abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 23
- 230000001419 dependent effect Effects 0.000 title description 17
- 201000010099 disease Diseases 0.000 title description 8
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims abstract description 171
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 claims abstract description 169
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 39
- 201000011510 cancer Diseases 0.000 claims abstract description 34
- 210000002865 immune cell Anatomy 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 202
- 108020004414 DNA Proteins 0.000 claims description 101
- 125000003729 nucleotide group Chemical group 0.000 claims description 82
- 239000002773 nucleotide Substances 0.000 claims description 79
- 210000002540 macrophage Anatomy 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 67
- 102000053602 DNA Human genes 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 52
- 230000011664 signaling Effects 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 46
- 230000001086 cytosolic effect Effects 0.000 claims description 27
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 20
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 17
- 201000001441 melanoma Diseases 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 210000001539 phagocyte Anatomy 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 10
- 230000016396 cytokine production Effects 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 230000008595 infiltration Effects 0.000 claims description 5
- 238000001764 infiltration Methods 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 208000007089 vaccinia Diseases 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 14
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 48
- 108030002637 Cyclic GMP-AMP synthases Proteins 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102000040430 polynucleotide Human genes 0.000 description 34
- 108091033319 polynucleotide Proteins 0.000 description 34
- 239000002157 polynucleotide Substances 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 210000004881 tumor cell Anatomy 0.000 description 22
- 102000014150 Interferons Human genes 0.000 description 20
- 108010050904 Interferons Proteins 0.000 description 20
- 210000000612 antigen-presenting cell Anatomy 0.000 description 20
- 229940079322 interferon Drugs 0.000 description 20
- 230000004913 activation Effects 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- -1 for example Proteins 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 238000011529 RT qPCR Methods 0.000 description 14
- 230000001640 apoptogenic effect Effects 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 230000000306 recurrent effect Effects 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 9
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 9
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 9
- 206010057249 Phagocytosis Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000003500 gene array Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000008782 phagocytosis Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000000172 cytosol Anatomy 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- FFKUHGONCHRHPE-UHFFFAOYSA-N 5-methyl-1h-pyrimidine-2,4-dione;7h-purin-6-amine Chemical compound CC1=CNC(=O)NC1=O.NC1=NC=NC2=C1NC=N2 FFKUHGONCHRHPE-UHFFFAOYSA-N 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 5
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 101001107784 Caenorhabditis elegans Deoxyribonuclease-2 Proteins 0.000 description 5
- 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 5
- 108091092356 cellular DNA Proteins 0.000 description 5
- 208000030381 cutaneous melanoma Diseases 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101150007193 IFNB1 gene Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091093105 Nuclear DNA Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 201000003708 skin melanoma Diseases 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 3
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 3
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 3
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 3
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 231100000065 noncytotoxic Toxicity 0.000 description 3
- 230000002020 noncytotoxic effect Effects 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034353 Integrase Human genes 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 208000002896 anal canal carcinoma Diseases 0.000 description 2
- 230000002223 anti-pathogen Effects 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004665 defense response Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 102000050022 human STING1 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 150000008298 phosphoramidates Chemical group 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 108010006908 signal sequence receptor Proteins 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- NFFMINWQORKRPB-UHFFFAOYSA-N 2-(6-aminohexyl)-7h-purin-6-amine Chemical compound NCCCCCCC1=NC(N)=C2NC=NC2=N1 NFFMINWQORKRPB-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- YNFSUOFXEVCDTC-UHFFFAOYSA-N 2-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=C2NC=NC2=N1 YNFSUOFXEVCDTC-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010000881 Acute myeloid leukaemia (in remission) Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 206010001244 Adenosquamous carcinoma of the cervix Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 208000011823 Juvenile amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091008121 PML-RARA Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000025316 Richter syndrome Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 101710124574 Synaptotagmin-1 Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108091061763 Triple-stranded DNA Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 201000007564 anal canal squamous cell carcinoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000011146 cervical adenosquamous carcinoma Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 description 1
- 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229940083118 mekinist Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000007398 protein translocation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000010472 type I IFN response Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000017807 undifferentiated carcinoma of nasopharynx Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Definitions
- the present disclosure relates, in general, to oligonucleotides that stimulate STING (STimulator of INterferon Genes) activity and increase activity of immune cells.
- STING activators STAVs
- STAVs STING activators
- RNA helicases retinoic acid inducible gene 1 (RIG-I) or melanoma differentiation associated antigen 5 (MDA5, also referred to as IFIH1 and helicard).
- T cells that recognize specific antigens presented on tumor cells constitutes an important host defense response that has evolved to eliminate the development of cancer (1).
- the mechanisms underlining the stimulation of antigen presenting cells (APC) and the priming of tumor specific T cells remains to be clarified but is thought to involve the generation of immuno stimulatory type I interferon (IFN) and other cytokines triggered by DNA from the engulfed cell (2-6).
- IFN immuno stimulatory type I interferon
- STING stimulator of interferon genes
- STING recognizes cyclic dinucleotides including c-di-GMP or c-di-AMP secreted by intracellular bacteria or cyclic-GMP-AMP (cGAMP) generated by the cellular synthase Cyclic GMP-AMP synthase (cGAS) following association with cytosolic dsDNA species (11, 12).
- cGAMP cyclic-GMP-AMP
- cGAS Cyclic GMP-AMP synthase
- microbial infected cells are potently able to activate APCs following engulfment, and can robustly generate anti-pathogen T-cells (16, 17). While DNA from engulfed cells is known to play a key role in stimulating APC's (18), how phagocytes differentiate between an apoptotic/tumorigenic cell and an infected cell, both of which harbor considerable amounts of cellular DNA, remains to be fully determined.
- dsDNA having a structure sufficient to stimulate an immune response is useful to activate STING (STimulator of INterferon Genes) and has an effect at stimulating immune response in vivo, suggesting the STING activators will be useful in the treatment of autoimmune disease, infection and cancer.
- the disclosure provides an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
- STING STimulator of INterferon Genes
- the dsDNA is approximately 30 nucleotides in length. In various embodiments the dsDNA is approximately 70 nucleotides in length. It is contemplated that the STING activator dsDNA can be 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90 nucleotides in length.
- the dsDNA is AT rich or GC rich.
- the activator sequence may consist of all A residues, all T residues, alternating A and T residues, or a mixture of A and T residues, e.g., wherein 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are A residues or T residues, and the remaining residues are the complementary nucleotide.
- the activator sequence may consist of all G residues, all C residues, alternating G and C residues, or a mixture of G and C residues, e.g., wherein 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are G residues or C residues, and the remaining residues are the complementary nucleotide.
- the activator polynucleotide may be a mixture of A, T, G and C nucleotides.
- the 5' end and/or the 3' end of the activator polynucleotide is modified.
- the 5' end is modified by phosphorothioate linkage.
- the 3' end is modified by phosphorothioate linkage.
- the first three nucleotides at the 5' end are modified by phosphorothioate linkage.
- the last three nucleotides at the 3' end are modified by phosphorothioate linkage.
- the activator nucleotide is modified every 2, 3, 4, or 5 nucleotides.
- the activator nucleotide is modified at every third base.
- the activator has a sequence as follows: Sense strand:
- composition comprising a STING activator as described herein and a pharmaceutically acceptable carrier.
- the composition is a sterile composition.
- a vector comprising a STING activator as described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
- dsDNA double stranded DNA
- a vaccine comprising a STING activator as described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
- the nucleotide is in a vector.
- the vector is a viral or a plasmid vector.
- the viral vector is selected from the group consisting of vesicular stomatitis virus (VSV), a lentivirus, an acdenovirus, an adeno- associated virus, a vaccinia virus and a modified vaccinia Ankara (MVA) virus.
- the disclosure also contemplates a method of activating STING in a subject in need thereof comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
- an activator of STING STimulator of INterferon Genes
- dsDNA double stranded DNA
- a method of stimulating an immune response in a subject in need thereof comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) as described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
- an activator of STING STimulator of INterferon Genes
- dsDNA double stranded DNA having a modified 5' end and comprising between 25 and 90 nucleotides
- the subject is suffering from cancer or a microbial infection.
- cancers and microbial infections contemplated herein are described further in the Detailed Description.
- the disclosure contemplates a method of decreasing the size of a tumor in a subject comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
- an activator of STING STimulator of INterferon Genes
- dsDNA double stranded DNA having a modified 5' end and comprising between 25 and 90 nucleotides
- a method of treating cancer in a subject comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
- an activator of STING STimulator of INterferon Genes
- dsDNA double stranded DNA having a modified 5' end and comprising between 25 and 90 nucleotides
- the cancer is ovarian cancer, colon cancer, melanoma, breast cancer or lung cancer.
- tumor size in the subject is decreased by about 25-50%, about 40-70% or about 50-90% or more.
- the STING activator is administered intratumorally, intravenously, intra-arterially, intraperitoneally, intranasally, intramuscularly, intradermally or subcutaneously.
- the STING activator induces infiltration of immune cells into the tumor.
- the immune cells are macrophages or other phagocytes.
- the STING activator oligonucleotide remains cytosolic in a cell.
- the STING activator induces CxcllO and/or type I IFN cytokine production.
- FIG. 1A-1J Various STING ligands with different sequences and polynucleotide length.
- Figure 1A-1C different sequence
- Figure 1D-1F different length of AT rich ligands
- Figure 1G-I different length of GC rich ligands
- IFNb ELISA assay of MEFs Figure 1A, ID, 1G
- hTERT Figure IB, IE, 1H
- IFNb ELISA assay Figure 1C
- qPCR of IFNb Figure IF- II
- Figure 1J Evaluation of DNA amount in B 16 OVA cells transfected with 3 ug of STAV.
- FIG. 2A-2L Activation of macrophages by exogenous cytosolic DNA (STAVs) in engulfed apoptotic cells.
- Figure 2A Confocal analysis and flow cytometry analysis of B 16 OVA cells (B 16) transfected with FAM labeled STAVs (green). DAPI (blue) and anti- Calreticulin (red) as counter staining.
- Figure 2B Gene array analysis of B 16 cells transfected with STAVs. Highest variable inflammation-related genes are shown.
- Figure 2C qPCR analysis of ⁇ , CxcllO and Ifit3 in B 16 OVA cells same as in ( Figure 2B).
- FIG. 2D Western blot analysis of STING, p65 and IRF3 in B 16 cells transfected with STAVs at following time points.
- Figure 2E Immunofluorescent analysis using anti-STING and anti-p65 in B 16 cells at 3 hours after transfection of STAVs.
- Figure 2F Schematic representation of the phagocytosis of B 16 cells by macrophages. B 16 cells were transfected by STAVs for 3 hours and irradiated by UV (120mJ/cm). The irradiated B 16 cells were feed to macrophages (M0) at 24 hours after UV irradiation.
- FIG. 2G Confocal analysis and
- Figure 2H Flow cytometry analysis in macrophages following cellular engulfment of B 16 cells transfected with FAM labeled STAVs.
- FIG. 3A-3D B16 OVA cells to feed to macrophages.
- B 16 OVA cells were transfected with 3 ug/ml of ISD-FITC for 24 hours and 48 hours.
- Figure 3A Flow cytometry analysis of B 16 OVA cells stained with propidium iodide and annexin V.
- Figure 3B Flow cytometry analysis for residual FITC-labelled DNA in B 16 OVA cells following UV irradiation.
- Figure 3c Western blot analysis using anti-OVA in B 16 OVA cells following UV irradiation. Beta actin was used as control.
- Figure 3D Flow cytometry analysis in macrophages following cellular engulfment of CFSE labelled B 16 OVA cells.
- FIG. 4A Flow cytometry analysis in macrophages following cellular engulfment of HEK293 cells (293) transfected with FAM labeled STAVs.
- Figure 4B Gene array analysis of WT and SKO macrophages following engulfment of irradiated 293 cells with/without STAVs. Highest variable inflammation-related genes are shown.
- FIG. 5A-5H Macrophage stimulation in trans by cytosolic DNA.
- Figure 5A Western blot analysis of STING and cGAS in mouse embryonic fibroblasts (MEFs).
- Figure 5B ELISA of IFN in WT, SKO and cGAS knock out (cGAS KO) transfected with STAVs.
- Figure 5C Schematic representation of the phagocytosis of MEFs by macrophages. qPCR analysis of CxcllO ( Figure 5D) and IFN ( Figure 5E) in WT and SKO macrophages following engulfment of UV irradiated WT, SKO and cGAS KO MEFs with STAVs.
- FIG. 5F ELISA of IFN in 293T and hTERT cells transfected with STAVs.
- Data is representative of at least three independent experiments. Error bars indicate s.d. *; p ⁇ 0.05, Student's t-test.
- Fig. 6A-6F Extrinsic activation of the cGAS/STING axis in macrophages.
- FIG. 6A qPCR analysis of CxcllO and IFN in WT, SKO, cGAS KO and TLR9 KO macrophages following engulfment of STAVs treated B 16 cells.
- Figure 6B cGAS expression by Western blot and cGAMP amount by a hybrid mass spectrometer.
- Figure 6C qPCR analysis of CxcllO in WT, SKO, and cGAS KO macrophages following engulfment of 293T cells containing STAVs. The 293T cells were reconstituted with pcGAS or pCMV as control vector.
- FIG. 6D Measurement of cGAMP levels by a hybrid mass spectrometer in 293T cells same as in (C).
- Figure 6E qPCR analysis of CxcllO in WT, SKO, and cGAS KO macrophages following engulfment of HTl 16 cells containing STAVs. The HTl 16 cells were reconstituted with pcGAS or pCMV as control vector.
- Figure 6F qPCR analysis of IFN in WT, SKO, cGAS KO, and Trexl KO macrophages following engulfment of B 16 cells infected with HSVy34.5. The HTl 16 cells were reconstituted with pcGAS or pCMV as control vector. Error bars indicate s.d. *; p ⁇ 0.05, Student's t-test.
- FIG. 7A-7C Activation of antigen presenting cells by STAVs.
- WT, SKO, cGAS KO macrophages were transfected with 3 ug/ml of ( Figure 7A) AT90ES or ( Figure 7B) cGAMP and ( Figure 7C) Ifnb treatment for 24 hours followed by pulsing with or without SIINFEKL.
- Antigen presentation was evaluated by flow cytometry analysis using antibody reacting with OVA peptide SIINFEKL bound to H-2Kb of MHC class I.
- Fig. 8A-8D Apoptotic cells containing STAVs escape degradation by DNase II.
- FIG. 8A Schematic representation of the phagocytosis of B 16 cells by DNase I, DNase II, or Trexl Knockout macrophages.
- B 16 cells were transfected by STAVs for 3 hours and irradiated by UV (120mJ/cm). The irradiated B 16 cells were feed to three different genotypes of macrophages (M0) at 24 hours after UV irradiation.
- FIG. 9A-9D Anti-tumor activity of STAVs in B16 OVA melanomas.
- Fig. 10A-10G Protection of lung metastasis by B16 OVA requires STING.
- FIG. 10A Schematic representation of the dead cell immunization.
- B16 OVA cells were transfected by STAVs for 3 hours and irradiated by UV (120mJ/cm). After 24 hours, WT, SKO, TLR9 KO, and cGAS KO mice were i.p. injected with the irradiated B16 cells with/without STAV, twice every week.
- Figure 10B LFNy measurement in splenocytes from WT, SKO, TLR9 KO, and cGAS KO mice at 7 days after the second immunization.
- Figure IOC Schematic representation of post-vaccination for B16 OVA mediated lung metastasis.
- STAVs Gene expression fold changes of ILLUMLNA array of B16 cells transfected with STAVs. Fold change analysis was performed between two groups and differentially expressed genes were selected based on threshold of Fold change > 3 from a comparison between untransfected and STAVs transfected B16 cells.
- Fig. 12 Fold changes of gene array analysis in B16 feeding macrophages.
- the term "induces or enhances an immune response” as used herein refers to causing a statistically measurable induction or increase in an immune response over a control sample to which the peptide, polypeptide or protein has not been administered.
- the induction or enhancement of the immune response results in a prophylactic or therapeutic response in a subject.
- Examples of immune responses are increased production of type I IFN, increased resistance to viral and other types of infection by alternate pathogens.
- STING includes, without limitation, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands, complementary sequences, peptides, polypeptides, proteins, homologous and/or orthologous STING molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.
- a "STING activator” or “STAV” as used herein refers to a nucleotide that when introduced into or produced by a cell can induce signaling through the STING protein.
- CDN cyclic dinucleotides
- the STAV is a double standard DNA molecule that when introduced into the cytosol of a cell activates STING signaling.
- the STAV dsDNA may have a modified 5' end and/or may have modified bases every 2, 3, 4 or 5 nucleotides throughout the nucleotide sequences.
- the STAV is about 20 to 90, 25 to 90, or 30 to 70 nucleotides in length, or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90 nucleotides in length.
- a "DNA Vaccine” or "DNA vector” as used herein refers to a synthetic DNA structure that can be transcribed in target cells and can comprise a linear nucleic acid such as a purified DNA, a DNA incorporated in a plasmid vector, or a DNA incorporated into any other vector suitable for introducing DNA into a host cell.
- the DNA vaccine can be naked DNA.
- a naked DNA vaccine is provided herein.
- the vaccine may comprise viruslike particles (VLPs).
- VSV cular stomatitis virus
- a VSV construct herein may be in any of several forms, including, but not limited to, genomic RNA, mPvNA, cDNA, part or all of the VSV RNA encapsulated in the nucleocapsid core, VSV complexed with compounds such as PEG and VSV conjugated to a nonviral protein.
- VSV vectors useful herein encompass replication-competent and replication-defective VSV vectors, such as, VSV vectors lacking G glycoprotein.
- VSV vectors refers to a polynucleotide construct designed for transduction/transfection of one or more cell types.
- VSV vectors may be, for example, "cloning vectors” which are designed for isolation, propagation and replication of inserted nucleotides, "expression vectors” which are designed for expression of a nucleotide sequence in a host cell, or a “viral vector” which is designed to result in the production of a recombinant virus or virus-like particle, or "shuttle vectors", which comprise the attributes of more than one type of vector.
- the present invention encompasses viral vectors, such as vesicular stomatitis virus (VSV), a lentivirus, an acdenovirus, an adeno-associated virus, a vaccinia virus, or a modified vaccinia Ankara (MVA) virus vectors that comprise nucleic acid encoding Zika virus proteins, such as an Env protein.
- VSV vesicular stomatitis virus
- a lentivirus lentivirus
- an acdenovirus an adeno-associated virus
- a vaccinia virus or a modified vaccinia Ankara (MVA) virus vectors that comprise nucleic acid encoding Zika virus proteins, such as an Env protein.
- MVA modified vaccinia Ankara
- the vectors can comprises a polynucleotide encoding a Zika protein as well as a polynucleotide encoding another protein that may improve efficacy of the vector
- chemokines such as for example, Mip
- co- stimulatory proteins such as for example, B7-1 and B7-2
- angiostatin such as for example, endostatin
- heat shock proteins such as for example gp96.
- polynucleotide and “nucleic acid”, used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple- stranded DNA, genomic DNA, cDNA, genomic RNA, mRNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases.
- the backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups.
- the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidates and thus can be a oligodeoxynucleoside phosphoramidate (P-NH2) or a mixed phosphoramidate-phosphodiester oligomer.
- P-NH2 oligodeoxynucleoside phosphoramidate
- Peyrottes et al. (1996) Nucleic Acids Res. 24: 1841- 8; Chaturvedi et al. (1996) Nucleic Acids Res. 24: 2318-23; Schultz et al. (1996) Nucleic Acids Res.
- a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer.
- polynucleotide sequence (such as referring to a SEQ ID NO) also includes the complement sequence.
- polynucleotides a gene or gene fragment, exons, introns, genomic RNA, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
- a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches.
- sequence of nucleotides may be interrupted by non-nucleotide components.
- a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
- Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support.
- Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
- a gene encodes a protein if transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system.
- coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings
- non-coding strand used as the template for transcription
- a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.
- Under transcriptional control is a term well understood in the art and indicates that transcription of a polynucleotide sequence depends on its being operably (operatively) linked to an element which contributes to the initiation of, or promotes, transcription.
- "Operably linked” refers to a juxtaposition wherein the elements are in an arrangement allowing them to function.
- heterologous polynucleotide or “heterologous gene” or “transgene” is any polynucleotide or gene that is not present in wild-type viral vector.
- a heterologous promoter is one which is not associated with or derived from the vector itself.
- a "host cell” includes an individual cell or cell culture which can be or has been a recipient of a vector(s) described herein.
- Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA
- a host cell includes cells transfected, transformed or infected in vivo or in vitro with a vector herein.
- a “vector” (sometimes referred to as gene delivery or gene transfer “vehicle”) refers to a macromolecule or complex of molecules comprising a polynucleotide to be delivered to a host cell, either in vitro or in vivo.
- the polynucleotide to be delivered may comprise a coding sequence of interest in gene therapy.
- Vectors include, for example, viral vectors (such as adenoviruses ("Ad"), adeno-associated viruses (AAV), and vesicular stomatitis virus (VSV) and retroviruses), liposomes and other lipid-containing complexes, and other macromolecular complexes capable of mediating delivery of a polynucleotide to a host cell.
- Vectors can also comprise other components or functionalities that further modulate gene delivery and/or gene expression, or that otherwise provide beneficial properties to the targeted cells.
- such other components include, for example, components that influence binding or targeting to cells (including components that mediate cell-type or tissue-specific binding); components that influence uptake of the vector nucleic acid by the cell;
- components that influence localization of the polynucleotide within the cell after uptake such as agents mediating nuclear localization
- components that influence expression of the polynucleotide also might include markers, such as detectable and/or selectable markers that can be used to detect or select for cells that have taken up and are expressing the nucleic acid delivered by the vector.
- markers such as detectable and/or selectable markers that can be used to detect or select for cells that have taken up and are expressing the nucleic acid delivered by the vector.
- Such components can be provided as a natural feature of the vector (such as the use of certain viral vectors which have components or functionalities mediating binding and uptake), or vectors can be modified to provide such functionalities.
- Other vectors include those described by Chen et al; BioTechniques, 34: 167- 171 (2003). A large variety of such vectors are known in the art and are generally available.
- expression vector refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules, siRNA, ribozymes, and the like.
- Expression vectors can contain a variety of control sequences, which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operatively linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well.
- vaccine refers to a composition comprising a vector comprising a STING activator as described herein, which is useful in the treatment of cancer or other conditions in which enhanced immune response is indicated. It is contemplated that the vaccine comprises a pharmaceutically acceptable carrier and/or an adjuvant. It is contemplated that vaccines are prophylactic or therapeutic.
- a “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs for the purpose of decreasing the risk of developing pathology.
- the compounds of the invention may be given as a prophylactic treatment to reduce the likelihood of developing a pathology or to minimize the severity of the pathology, if developed.
- a “therapeutic” treatment is a treatment administered to a subject who exhibits signs or symptoms of pathology for the purpose of diminishing or eliminating those signs or symptoms.
- the signs or symptoms may be biochemical, cellular, histological, functional, subjective or objective.
- APC antigen presenting cell
- DC dendritic cell
- the term “dendritic cell” or “DC” refers to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. These cells are characterized by their distinctive morphology, high levels of surface MHC-class II expression.
- DCs can be isolated from a number of tissue sources. DCs have a high capacity for sensitizing MHC- restricted T cells and are very effective at presenting antigens to T cells in situ.
- the antigens may be self-antigens that are expressed during T cell development and tolerance, and foreign antigens that are present during normal immune processes.
- the "treatment of cancer” refers to one or more of the following effects: (1) inhibition, to some extent, of tumor growth, including, (i) slowing down and (ii) complete growth arrest; (2) reduction in the number of tumor cells; (3) maintaining tumor size; (4) reduction in tumor size; (5) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of tumor cell infiltration into peripheral organs; (6) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of metastasis; (7) enhancement of anti-tumor immune response, which may result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing the growth of a tumor, (iv) reducing, slowing or preventing invasion and/or (8) relief, to some extent, of the severity or number of one or more symptoms associated with the disorder.
- isolated refers to a polynucleotide, virus or antigenic composition that is removed from its native environment.
- an isolated biological material is free of some or all cellular components, i.e., components of the cells in which the native material occurs naturally (e.g., cytoplasmic or membrane component).
- a polynucleotide, virus or antigenic composition is deemed isolated if it is present in a cell extract or supernatant.
- an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment.
- purified refers to a virus or immunogenic composition that has been isolated under conditions that reduce or eliminate the presence of unrelated materials, i.e., contaminants, including endogenous materials from which the composition is obtained.
- a purified virion is substantially free of host cell or culture components, including tissue culture or cell proteins and non-specific pathogens.
- purified material substantially free of contaminants is at least 50% pure; at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or even at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.
- composition refers to a composition suitable for administration to a subject animal, including humans and mammals.
- a pharmaceutical composition comprises a pharmacologically effective amount of a virus or antigenic composition of the invention and also comprises a pharmaceutically acceptable carrier.
- a pharmaceutical composition encompasses a composition comprising the active ingredient(s), and the inert ingredient(s) that make up the pharmaceutically acceptable carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients.
- the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound or conjugate of the present invention and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier include any and all clinically useful solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, and excipients, such as a phosphate buffered saline solution, 5% aqueous solution of dextrose or mannitol, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents and/or adjuvants. Suitable pharmaceutical carriers and formulations are described in Remington's Pharmaceutical Sciences, 19th Ed. (Mack
- compositions useful for the composition depend upon the intended mode of administration of the active agent. Typical modes of administration include, but are not limited to, enteral (e.g. , oral) or parenteral (e.g. , subcutaneous, intramuscular, intravenous or intraperitoneal injection; or topical, transdermal, or transmucosal administration).
- enteral e.g. , oral
- parenteral e.g. , subcutaneous, intramuscular, intravenous or intraperitoneal injection; or topical, transdermal, or transmucosal administration.
- a "pharmaceutically acceptable salt” is a salt that can be formulated into a compound or conjugate for pharmaceutical use including, e.g. , metal salts (sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.
- pharmaceutically acceptable refers to a material which is not biologically or otherwise undesirable, i.e. , the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained, or when administered using routes well-known in the art, as described below.
- STING Stimulator of Interferon Genes
- TM transmembrane
- ER endoplasmic reticulum
- Human STING is a 379 amino acid protein, having an amino acid sequence set out in Genbank Accession No. NP_938023 and nucleotide sequence set out in Genbank Accession No. NM_198282, though alternate protein isoforms may exist (Genbank Accession Nos. NP_001288667.1,
- Loss of STING reduced the ability of polyLC to activate type I IFN and rendered murine embryonic fibroblasts lacking STING ( _/ ⁇ MEFs) generated by targeted homologous recombination, susceptible to vesicular stomatitis virus (VSV) infection.
- VSV vesicular stomatitis virus
- RNAi ablation of TRAPP inhibited STING function and impeded the production of type I IFN in response to polylC.
- STING itself binds nucleic acids including single- and double- stranded DNA such as from pathogens and apoptotic DNA, and plays a central role in regulating proinflammatory gene expression in inflammatory conditions such as DNA- mediated arthritis and cancer. Certain inhibitors and activators of STING are discussed in International Patent Publication No. WO 2013/166000. STING Activators
- cyclic dinucleotides are natural activators of STING, but are not often induced in tumor cells, or are used by tumor cells to evade tumor cell death. CDNs typically stay in the nucleus and are not leaked into the cytosol, which helps tumors evade immune cells.
- the inventors developed a nucleotide that could stay in the cytosol and induce STING activation in response to free dsDNA, similar to the situation in apoptosis of a cell.
- the STAV is a double stranded DNA molecule that when introduced into the cytosol of a cell activates STING signaling.
- the STAV is about 20 to 90, 25 to 90, or 30 to 70 nucleotides in length, or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90 nucleotides in length.
- the activator oligonucleotide herein is AT (adenine-thymine) rich or GC (guanine-cytosine) rich.
- the activator sequence may consist of all A residues, all T residues, alternating A and T residues, or a mixture of A and T residues, e.g., wherein approximately 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are A residues or T residues, and the remaining residues are the complementary nucleotide.
- the activator sequence may consist of all G residues, all C residues, alternating G and C residues, or a mixture of G and C residues, e.g., wherein approximately 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are G residues or C residues, and the remaining residues are the complementary nucleotide.
- the activator polynucleotide may be a mixture of A, T, G and C nucleotides.
- the activator has a sequence as follows: Sense strand:
- the STAV dsDNA may have a modified 5' end and/or may have modified bases every 2, 3, 4 or 5 nucleotides throughout the nucleotide sequences.
- the 5' end and/or 3' end may be modified.
- the 5' end is modified by phosphorothioate linkage.
- the 3' end is modified by phosphorothioate linkage.
- the first three nucleotides at the 5' end are modified by phosphorothioate linkage.
- the last three nucleotides at the 3' end are modified by phosphorothioate linkage.
- the activator nucleotide is modified every 2, 3, 4, or 5 nucleotides.
- the activator nucleotide is modified at every third base.
- a STAV oligonucleotide may comprise combinations of phosphorothioate internucleotide linkages and at least one internucleotide linkage selected from the group consisting of: alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and/or combinations thereof.
- a STAV oligonucleotide optionally comprises at least one modified nucleobase comprising, peptide nucleic acids, locked nucleic acid (LNA) molecules, analogues, derivatives and/or combinations thereof.
- LNA locked nucleic acid
- Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
- base any nucleobase
- nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U).
- Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2' deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2- (imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-
- oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide.
- moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA 1989, 86, 6553), cholic acid (Manoharan et al. Bioorg. Med. Chem. Let. 1994, 4, 1053), a thioether, e.g., hexyl-5-tritylthiol (Manoharan et al. Ann. N.Y. Acad. Sci. 1992, 660, 306;
- a phospholipid e.g., di-hexadecyl-rac-glycerol or triethylammonium l,2-di-0-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.
- oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.
- the nucleic acid molecule of the present invention is conjugated with another moiety including but not limited to abasic nucleotides, polyether, polyamine, polyamides, peptides, carbohydrates, lipid, or polyhydrocarbon compounds.
- abasic nucleotides polyether, polyamine, polyamides, peptides, carbohydrates, lipid, or polyhydrocarbon compounds.
- these molecules can be linked to one or more of any nucleotides comprising the nucleic acid molecule at several positions on the sugar, base or phosphate group.
- use of modifications such as the use of LNA monomers to enhance the potency, specificity and duration of action and broaden the routes of administration of oligonucleotides comprised of current chemistries such as MOE, ANA, FANA, PS etc.
- LNA modified oligonucleotide may have a size similar to the parent compound or may be larger or preferably smaller. It is preferred that such LNA-modified oligonucleotides contain less than about 70%, more preferably less than about 60%, most preferably less than about 50% LNA monomers and that their sizes are between about 5 and 25 nucleotides, more preferably between about 12 and 20 nucleotides.
- Preferred modified oligonucleotide backbones comprise, but not limited to,
- aminoalkylphosphotriesters methyl and other alkyl phosphonates comprising 3' alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates,
- thionoalkylphosphonates thionoalkylphosphotriesters, and boranophosphates having normal 3'- 5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.
- Various salts, mixed salts and free acid forms are also included.
- Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane
- backbones sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH 2 component parts.
- both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.
- the base units are maintained for hybridization with an appropriate nucleic acid target compound.
- an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA).
- PNA peptide nucleic acid
- the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone.
- the nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
- phosphorothioate backbones and oligonucleosides with heteroatom backbones and in particular- CH 2 -NH-O-CH 2 -, --CH 2 --N(CH 3 )--0--CH 2 -known as a methylene (methylimino) or MMI backbone, -CH 2 -0-N(CH 3 )-CH 2 -, -CH 2 N(CH 3 )-N(CH 3 )CH 2 -and-0--N(CH 3 )-CH 2 — CH2- - wherein the native phosphodiester backbone is represented as— O— P— O— CH 2 — of the above referenced U.S. Pat. No.
- Modified oligonucleotides may also contain one or more substituted sugar moieties.
- Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; 0-, S-, or N- alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or O alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C to CO alkyl or C 2 to CO alkenyl and alkynyl.
- oligonucleotides comprise one of the following at the 2' position: C to CO, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, CI, Br,
- CN CF 3 , OCF 3 , SOCH 3 , S0 2 CH 3 , ON0 2 , N0 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties.
- a preferred modification comprises 2'-methoxyethoxy
- a further preferred modification comprises 2'-dimethylaminooxyethoxy, i.e., a 0(CH 2 ) 2 0N(CH 3 ) 2 group, also known as 2'- DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-0-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-0-CH 2 -0-CH 2 - N(CH 2 ) 2 .
- Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
- Oligonucleotides may also comprise nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
- nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
- Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2- propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2- thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8- hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5- trifluoromethyl and other 5-
- nucleobases comprise those disclosed in "The Concise Encyclopedia of Polymer Science And Engineering", pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., “Angewandle Chemie, International Edition", 1991, 30, page 613, and those disclosed by Sanghvi, Y. S., Chapter 15, "Antisense Research and
- nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention.
- These comprise 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5- propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. (Sanghvi, Y. S., Crooke, S. T.
- the disclosure provides a method of activating STING in a subject in need thereof comprising administering a composition comprising an activator of STING described herein, wherein the activator induces STING signaling.
- a method of stimulating an immune response in a subject in need thereof comprising administering a composition comprising an activator of STING described herein.
- the immune response is an ongoing immune response in cancer, a microbial infection or an autoimmune disease.
- the STING activator may be administered prophylactically in a disease or disorder in which an immune response is in a remission phase, e.g., in cancer or an autoimmune disease.
- the disclosure provides a method of decreasing the size of a tumor in a subject having a tumor or cancer comprising administering a composition comprising an activator of STING. Also provided is a method for treating cancer or preventing the recurrence of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a STAV or a pharmaceutical composition comprising a STAV or vector or vaccine comprising a STAV as described herein.
- Exemplary conditions or disorders that can be treated with STAVs include cancers, such as esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic
- RUNX1-RUNX1T1 adult acute myeloid leukemia with t(9;l l)(p22;q23); MLLT3-MLL; adult acute promyelocytic leukemia with t(15;17)(q22;ql2); PML-RARA; alkylating agent-related acute myeloid leukemia, chronic lymphocytic leukemia, richter's syndrome; Waldenstrom macroglobulinemia, adult glioblastoma; adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent Ewing sarcoma/ peripheral primitive neuroectodermal tumor, recurrent neuroblastoma; recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer; MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma; recurrent nasopharyngeal undifferent
- metastatic anal canal carcinoma recurrent anal canal carcinoma, recurrent head and neck cancer
- carcinoma squamous cell of head and neck, head and neck squamous cell carcinoma (HNSCC)
- HNSCC head and neck squamous cell carcinoma
- colon cancer gastric cancer, advanced GI cancer, gastric adenocarcinoma; gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma; bone sarcoma, thymic carcinoma, urothelial carcinoma, recurrent merkel cell carcinoma; stage III merkel cell carcinoma; stage IV merkel cell carcinoma, myelodysplastic syndrome and recurrent mycosis fungoides and Sezary syndrome.
- cancers that can be treated with the present invention include ovarian cancer, colon cancer, melanoma, breast cancer or lung cancer.
- the methods herein reduce tumor size or tumor burden in the subject, and/or reduce metastasis in the subject. In various embodiments, the methods reduce the tumor size by 10%, 20%, 30% or more. In various embodiments, the methods reduce tumor size by 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%. [0097] It is contemplated that the methods herein reduce tumor burden, and also reduce or prevent the recurrence of tumors once the cancer has gone into remission.
- the STAV or STAV compositions described herein modulates immune cells in a tumor.
- the STAV or STAV compositions increases the number of macrophages or other phagocytes or antigen presenting cells in a tumor and/or increases phagocytic activity of cells in the area of the tumor.
- Other conditions or disorders contemplated for treatment with a STAV as described herein include infectious diseases or autoimmune disease in which an increase in immune response may be desired.
- infectious diseases or autoimmune disease include, but are not limited to, an inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), a peripheral vascular disease, a cerebral vascular accident (stroke), a disorder characterized by lesions having inflammatory cell infiltration, a disorder where amyloid plaques are present in the brain (e.g., Alzheimer's disease), Aicardi-Goutieres syndrome, juvenile arthritis, osteoporosis, amyotrophic lateral sclerosis, or multiple sclerosis.
- an inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease
- peripheral vascular disease e.g., a peripheral vascular disease
- stroke cerebral vascular accident
- a disorder characterized by lesions having inflammatory cell infiltration e.g., Alzheimer's disease
- Aicardi-Goutieres syndrome
- Exemplary microbial infections contemplated include viral, bacterial or fungal infection.
- Many methods may be used to administer or introduce the dsDNA STAVs or vectors, vaccines or viral particles comprising the dsDNA into individuals (i.e., including subjects or patients), including but not limited to, intratumorally, intravenously, intra-arterially,
- a vector or viral particle is administered is a primate, or in other examples, a mammal, or in other examples, a human, but can also be a non- human mammal including but not limited to cows, horses, sheep, pigs, fowl, cats, dogs, hamsters, mice and rats.
- the individual can be any animal in which a vector or virus is capable introducing the dsDNA and results in activation of STING.
- compositions comprising dsDNA, vectors, vaccines or viral particles wherein said compositions can further comprise a pharmaceutically acceptable carrier.
- amount of vector(s) to be administered will depend on several factors, such as route of administration, the condition of the individual, the degree of aggressiveness of the malignancy, and the particular vector employed. Also, the vector may be used in conjunction with other treatment modalities.
- vaccines or viral particles from about 10 up to about 10 7 p.f .u., in other examples, from about 10 3 up to about 10 6 p.f.u., and in other examples, from about 10 4 up to about 10 5 p.f.u. is administered.
- a polynucleotide construct i.e., not packaged as a virus
- about 0.01 ⁇ g to about 100 ⁇ g of a viral construct of the present invention can be administered, in other examples, 0.1 ⁇ g to about 500 ⁇ g, and in other examples, about 0.5 ⁇ g to about 200 ⁇ g can be administered.
- More than one vector can be administered, either simultaneously or sequentially. Administrations are typically given periodically, while monitoring any response. Administration can be given, for example, intramuscularly, intravenously, intratumorally or intraperitoneally.
- an effective amount of the dsDNA, vector(s), vaccines or viral particles is administered.
- An "effective amount” is an amount sufficient to achieve a desired biological effect such as to induce enough humoral or cellular immunity. This may be dependent upon the type of vaccine, the age, sex, health, and weight of the recipient. Examples of desired biological effects include, but are not limited to, increase in immune response, increase in STING stimulation, decrease in tumor size or tumor burden, production of no symptoms or reduction in symptoms related to disease or condition being treated.
- a vaccine or composition of the present invention is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient that enhances at least one primary or secondary humoral or cellular immune response against a tumor or other targeted cell or microbe.
- the STING activator increases infiltration of immune cells into the tumor or site of infection.
- the immune cells are macrophages, dendritic cells or other phaogcytes.
- the composition can also contain minor amounts of wetting or emulsifying agents or pH buffering agents.
- the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
- Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a
- hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent.
- an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.
- compositions of the present disclosure containing the inhibitors described herein as an active ingredient may contain pharmaceutically acceptable carriers or additives depending on the route of administration.
- carriers or additives include water, a pharmaceutical acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, gelatin, agar, diglycerin, glycerin, propylene glycol, polyethylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like.
- Additives used are chosen from, but not limited to, the above or combinations thereof, as appropriate, depending on the dosage
- Formulation of the pharmaceutical composition will vary according to the route of administration selected (e.g., solution, emulsion).
- An appropriate composition comprising the inhibitor, e.g., an antibody, to be administered can be prepared in a physiologically acceptable vehicle or carrier.
- suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
- Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers.
- aqueous carriers e.g., sterile phosphate buffered saline solutions, bacteriostatic water, water, buffered water, 0.4% saline, 0.3% glycine, and the like, and may include other proteins for enhanced stability, such as albumin, lipoprotein, globulin, etc., subjected to mild chemical modifications or the like.
- Therapeutic formulations of the inhibitors are prepared for storage by mixing the inhibitor having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol;
- polypeptides such as serum albumin, gelatin, or immunoglobulins
- hydrophilic polymers such as polyvinylpyrrolidone
- amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine
- chelating agents such as EDTA
- sugars such as sucrose, mannitol, trehalose or sorbitol
- salt-forming counter-ions such as sodium
- metal complexes e.g., Zn- protein complexes
- non-ionic surfactants such as TWEENTM, PLURONICSTM or polyethylene glycol (PEG).
- the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
- Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
- the active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example,
- hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
- macroemulsions for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
- formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
- the dose of vector, vaccine or viral particle to be employed in the formulation will also depend on the route of administration, and the nature of the patient, and should be decided according to the judgment of the practitioner and each patient's circumstances according to standard clinical techniques.
- the exact amount of vector or virus utilized in a given preparation is not critical provided that the minimum amount of virus necessary to produce immunologic activity is given.
- Effective doses of the vector or viral particle of the invention may also be extrapolated from dose-response curves derived from animal model test systems.
- administration is performed at the site of a cancer or affected tissue needing treatment by direct injection into the site or via a sustained delivery or sustained release mechanism, which can deliver the formulation internally.
- a sustained delivery or sustained release mechanism which can deliver the formulation internally.
- biodegradable microspheres or capsules or other biodegradable polymer configurations capable of sustained delivery of a composition e.g., a soluble polypeptide, antibody, or small molecule
- a composition e.g., a soluble polypeptide, antibody, or small molecule
- Therapeutic compositions may also be delivered to the patient at multiple sites.
- the multiple administrations may be rendered simultaneously or may be administered over a period of time. In certain cases it is beneficial to provide a continuous flow of the therapeutic composition.
- Additional therapy may be administered on a period basis, for example, hourly, daily, every other day, twice weekly, three times weekly, weekly, every 2 weeks, every 3 weeks, monthly, or at a longer interval.
- a STAV of the present disclosure or composition thereof is administered with a second agent useful for treating a condition or disorder for which STAV therapy is used, e.g., cancer, infection or autoimmune disease.
- a second agent useful for treating a condition or disorder for which STAV therapy is used e.g., cancer, infection or autoimmune disease.
- Concurrent administration of two therapeutic agents does not require that the agents be administered at the same time or by the same route, as long as there is an overlap in the time period during which the agents are exerting their therapeutic effect. Simultaneous or sequential administration is contemplated, as is administration on different days or weeks.
- the second agent may be other therapeutic agents, such as cytokines, growth factors, other inhibitors and antibodies to target antigens useful for treating cancer or immunological disorders, for example ipilimumab (YERVOY ® , Bristol-Myers Squibb Company), an antibody to CTLA-4; bevacizumab (AVASTIN®, Genentech), an antibody to VEGF-A; erlotinib (TARCEVA®, Genentech and OSI Pharmaceuticals), a tyrosine kinase inhibitor which acts on EGFR, dasatinib (SPRYCEL®, Bristol-Myers Squibb Company), an oral Bcr-Abl tyrosone kinase inhibitor; IL-21; pegylated IFN-oc2b; axitinib (INLYTA®, Pfizer, Inc.), a tyrosine kinase inhibitor; and trametinib (MEKINIST®, GlaxoSmithK
- the STAVs of the present disclosure and second agent may be given simultaneously, in the same formulation. It is further contemplated that the STAV and second agent are administered in a separate formulation and administered concurrently, with
- a STAV is administered prior to administration of the second agent.
- Prior administration refers to administration of a STAV within the range of one week prior to treatment with the second agent, up to 30 minutes before administration of the second agent. It is further contemplated that a STAV is administered subsequent to administration a second agent. Subsequent administration is meant to describe administration from 30 minutes after STAV treatment up to one week after STAV administration.
- adjunct therapies may be administered, where appropriate.
- the patient may also be administered surgical therapy, chemotherapy, a cytotoxic agent, photodynamic therapy or radiation therapy where appropriate.
- the administration also includes use of a radiotherapeutic agent or radiation therapy.
- the radiation therapy administered in combination with an antibody composition is administered as determined by the treating physician, and at doses typically given to patients being treated for cancer.
- a cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
- the term is intended to include radioactive isotopes (e.g., 1131, 1125, Y90 and Rel86), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin or synthetic toxins, or fragments thereof.
- a non-cytotoxic agent refers to a substance that does not inhibit or prevent the function of cells and/or does not cause destruction of cells.
- a non-cytotoxic agent may include an agent that can be activated to be cytotoxic.
- a non-cytotoxic agent may include a bead, liposome, matrix or particle (see, e.g., U.S. Patent Publications 2003/0028071 and 2003/0032995 which are incorporated by reference herein). Such agents may be conjugated, coupled, linked or associated with an antibody according to the disclosure.
- Chemotherapeutic agents contemplated for use with the antibodies of the present disclosure include, but are not limited to those listed in Table I:
- kits which comprise one or more compounds or compositions packaged in a manner which facilitates their use to practice methods of the disclosure.
- a kit includes a compound or composition described herein (e.g., a composition comprising a target- specific antibody alone or in combination with another antibody or a third agent), packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition in practicing the method.
- the compound or composition is packaged in a unit dosage form.
- the kit may further include a device suitable for administering the
- the kit contains a label that describes use of the inhibitor compositions.
- Mouse genotypes from tail biopsies were determined by using real-time PCR with specific probes designed for each gene by commercial vendor
- B 16-OVA cells B 16 were kindly provided by Dr. Eli Gilboa (University of Miami) and cultured in complete Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) including 10% heat-inactivated fetal calf serum (FCS, Invitrogen). 293, 293T cells and hTERT cells were purchased from ATCC. Mouse embryonic fibroblasts (MEFs) were obtained from el 3.5 embryos by a standard procedure.
- DMEM Dulbecco's Modified Eagle Medium
- FCS heat-inactivated fetal calf serum
- Bone marrow derived macrophages were isolated from hind-limb femurs of 8-10 weeks old WT, SKO, cGASKO, TLR9KO, DNase IKO, DNase II KO, or DNase III (Trexl) KO mice. Briefly, the marrow cells were flushed from the bones with complete DMEM with a 26 gauge needle. The cells were cultured in complete DMEM (Invitrogen) including 10 ng/ml of Mouse Recombinant Colony-Stimulating Factor (M- CSF, R&D Systems,) for 10 to 14 days.
- complete DMEM Invitrogen
- M- CSF Mouse Recombinant Colony-Stimulating Factor
- STING-dependent, TLR9-independent adjuvants STAVs.
- a ssDNA sense strand modified with Phosphorothioates (S-oligos) at the end (polyA90mer) was annealed to ssDNA antisense strand with same modification as anti-sense strand (polyT90mer); STAVs.
- S-oligos STING-dependent, TLR9-independent adjuvants
- ⁇ was cultured as described above and seeded on 12 well plates (2xl0 5 cells/well).
- B 16-OVA cells were transfected with STAVs at 3 ug/ml for 3 hours and irradiated by a UVC500 UV crosslinker at 120 mJ/cm followed by 24 hour incubation.
- the treated B 16-OVA cells were added to macrophages for 6 hours.
- the macrophages were harvested for RNA extraction for qPCR and Gene array analysis.
- RNA was extracted from cells using Trizol method and reverse transcribed by M-MLV reverse transcriptase (Promega). Real-time PCR was performed with the TaqMan gene Expression Assay (Ifn- ⁇ : Mm010439546, CxcllO : Mm00445235 ; Applied Biosystems).
- B 16-OVA cells were transfected with 3 ⁇ g/mL STAVs for 3 hours and then were treated by UV light (120 mJ/cm 2 ). After 24 hours at 37°C, 5% C0 2 , cells were collected and fed to bone marrow-derived macrophages for 6 hours. B 16-OVA cells viability was assessed by flow cytometric analysis with a FACSCantoII (Becton Dickinson, USA) after staining with 1 ⁇ g/mL propidium iodide (eBiosciences) and APC-labeled annexin V (eBiosciences).
- FACSCantoII Becton Dickinson, USA
- Pellets were further extracted in 20% (vol/vol) methanol with 2% HAc twice and all extracts were pooled.
- cGAMP was then enriched by solid-phase extraction (SPE) using HyperSep Aminopropyl SPE Columns (Thermo Scientific) as previously described in Gao et al, 2015. Briefly, columns were activated by 100% methanol and washed twice with 2% HAc; after drawing through the extracts, columns were washed twice with 2% HAc and once with 80% methanol, and finally eluted with 2% (vol/vol) ammonium hydroxide in 80% methanol.
- the eluents were spin-vacuumed to dryness, reconstituted in liquid chromatography (LC)/MS -grade water and stored at -20 °C before subject to LC/MS analysis. Chromatography was performed using a Thermo Scientific Surveyor MS Pump Plus pump and Micro AS autosampler. The separation was isocratic on a Water's XBridge Amide column (3.5 urn, 2.1x100 mm) at 200 ul/min using 18:82
- the standard electrospray source was used operated in negative ion mode.
- cGAMP was quantitated using the m/z 522 product ion from the collision-induced dissociation of the deprotonated parent ion at m/z 673.
- the c-di-GMP component was quantitated from the m/z 344 product ion originating from the deprotonated m/z 689 parent.
- mice were subcutaneously injected with 5xl0 5 cells of B 16-OVA on the right flank.
- 10 ⁇ g of STAVs was injected intratumorally (i.t.) every three days 3 times.
- mice were intravenously (i.v.) injected with B 16 OVA cells (1 x 10 5 cells / mouse).
- mice were injected intraperitoneally (i.p.) with UV irradiated B 16 OVA cells (1 x 10 6 cells / mouse).
- B 16-OVA cells were transfected with STAV at 3 ⁇ g/ml for 3 hours and irradiated by a UVC500 UV crosslinker at 120 mJ/cm followed by 24 hours incubation.
- IFNP ELISA 1 x 10 6 splenocytes were plated and stimulated with SIINFEKEL peptide (10 ⁇ g/ml). At 2 days after stimulation, the supernatant was harvested and IFNP production was estimated by BD mouse IFNp kit.
- an AT rich STING activating dsDNA ligand of 90 bp with modified 5'-ends (referred to as STAV) was used for further study.
- STAV AT rich STING activating dsDNA ligand of 90 bp with modified 5'-ends
- transfected cytosolic DNA could stimulate intrinsic STING signaling within the treated cell and facilitate the production of immunoregulatory cytokines that may provoke APC activation.
- STING acts extrinsically or intrinsically within the engulfed cell itself
- mouse embryonic fibroblasts (MEFs) that lacked STING or cGAS were treated with STAVs and confirmed that both STING and cGAS were required to produce cytokines such as type I IFN in the presence of cytosolic DNA ( Figures 5A and 5B).
- UV treated MEFs were then incubated with macrophages to ascertain the latter' s activation (Figure 5C).
- CAD caspase activated DNAse
- nucleosomes 14, 19
- fragments of nuclear DNA sufficient to activate STING may not be generated, nor escape into the cytosol to activate STING signaling.
- STING but not cGAS, is essential for the activation of APCs following cellular engulfment.
- B 16 cell by cGAS and these ligands are able to activate STING extrinsically within the APC, in trans.
- cGAS was expressed in B 16 cells and mass spectrometry showed that STAV treated, but not untreated B 16 cells, produced CDNs ( Figure 6B) and can likely also act in trans.
- STAVs transfected into cells can extrinsically activate the cGAS/STING axis in macrophages.
- STAVs can generate CDNs within the treated cell which can also act in trans to stimulate extrinsic STING signaling in APCs.
- reconstitution of cGAS for example within a tumor cell, can generate CDNs which are able to similarly act in trans to stimulate the activation of macrophages via STING.
- host macrophages can distinguish between a viral infected and uninfected dying cell predominantly through cGAS/STING detection of viral cytoplasmic DNA, analogous to STAVs.
- CDNs generated within a cell exhibit considerable ability to stimulate macrophages in trans
- CDNs were directly transfected into B 16 and 293T cells and the cells fed to macrophages. This analysis indicated that tumor cells containing exogenously added CDN's were readily engulfed by macrophages, but were not potent activators of STING signaling in trans or of macrophage activation (Figure 5). This is in contrast to when the cGAS was transfected within the tumor cell to generate endogenous CDNs. In contrast, the direct transfection of CDNs or indeed STAVs into APCs were readily able to induce their activation and to enhance the cross presentation of antigen in a STING specific manner (Figure 7).
- cytosolic DNA STAVs
- CDNs cytosolic DNA
- STAVs cytosolic DNA
- STAVs cytosolic DNA
- not cellular DNA was able to stimulate APCs in trans.
- Nuclear DNA, and plausibly mitochondrial DNA undergoes degradation during the apoptotic process.
- the responsible nucleases within the nuclei which cleaves genomic DNA between nucleosomes involves CAD (caspase activated DNAse) (14, 21).
- CAD caspase activated DNAse
- DNases such as CAD efficiently degrade self-DNA within apoptotic cells to help prevent the activation of macrophages.
- DNasell in APCs predominantly ensures that any engulfed apoptotic DNA that escapes degradation is broken down in lysosomal compartments into non-STING activating nucleotides.
- cells containing cytosolic DNA (STAVs) or cytoplasmic viral DNA likely escape degradation in the dying cell and are able to stimulate extrinsic cGAS/STING signaling, prior to degradation of by DNasell.
- CDN's as DAMPs may better avoid degradation following engulfment and enable a phagocyte to determined that the cell has been infected or undergone DNA damage, and become activated.
- mice were inoculated intravenously with B 16-OVA melanoma cells to indue tumors and subsequently post-vaccinated with B 16-OVA cells loaded with STAVs (Figure IOC).
- Results showed that the B 16 OVA tumors killed the majority of mice within 40 days ( Figure 10D).
- mice treated with B 16-OVA STAVs had a median half-life of 70 days, with 40% of the mice alive after 100 days ( Figure 10D).
- cells containing STAVs may provide an effective treatment for the prevention of cancer.
- cytosolic dsDNA species present within a dying cell can activate extrinsic STING signaling in phagocytes likely following association with cGAS which would generate CDNs. It is likely that the cytosolic DNA species avoid being degraded by nuclear DNAses, responsible for degrading genomic DNA. Such cytosolic species appear significantly more capable of activating STING in phagocytes, likely as a result of avoiding being degraded within the apoptotic cell. DNAse resistant cytosolic species were thus more competent at activating STING in trans.
- CDNs generated from an infected or damaged cell are able to directly activate STING-dependent signaling in APC's in trans to trigger inflammatory responses, the cross-presentation of antigen and the spontaneous generation of T cells.
- CDN's generated within a dying cell are also predominantly resistant to the activity of DNAses within the engulfed phagocyte, unlike susceptible cellular DNA, which makes them highly efficient at stimulating extrinsic STING signaling. It is likely that tumorigenic cells closely mimic normal cells undergoing apoptosis and avoid triggering STING signaling. Thus, tumorigenic cells are predominantly non-immunogenic.
- the data indicates that numerous tumor cells exhibit defective STING signaling. This would presumably enable the damaged cell to avoid alerting the immune system for removal and for antigen presentation. However, the data also indicates that by suppressing pathogen or DNA damaged driven CDN generation, an engulfed cell would also avoid the activation of the APC itself. This may help explain why the STING/cGAS pathway is so commonly deregulated in certain cancers. The results further indicate that reconstitution of CDN's and STING signaling may not only alert the immune system to the damaged/infected/tumor cell, but also potently trigger cytokine production, inflammatory responses, antigen cross-presentation and spontaneous T cell generation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates, in general, to oligonucleotides that stimulate STING (STimulator of INterferon Genes) activity and increase activity of immune cells. The disclosed STING activators (STAVs) are useful in the treatment of cancer and other immune-mediated conditions.
Description
STING-DEPENDENT ACTIVATORS FOR TREATMENT OF DISEASE
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No. 62/518,292 filed on June 12, 2017, the disclosure of which is hereby incorporated by reference in its entirety.
INCORPORATION BY REFERENCE OF MATERIALS SUBMITTED
ELECTRONICALLY
[0002] This application contains, as a separate part of the disclosure, a sequence listing in computer readable form (Filename: 50648A_Seqlisting.txt; Size: 4,094 Bytes; Created: June 11, 2018), which is incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0003] The present disclosure relates, in general, to oligonucleotides that stimulate STING (STimulator of INterferon Genes) activity and increase activity of immune cells. The disclosed STING activators (STAVs) are useful in the treatment of cancer and other immune-mediated conditions.
BACKGROUND
[0004] Cellular host defense responses to pathogen invasion principally involves the detection of pathogen associated molecular patterns (PAMPs) such as viral nucleic acid or bacterial cell wall components including lipopolysaccharide or flagellar proteins that results in the induction of anti-pathogen genes. For example, viral RNA can be detected by membrane bound Toll-like receptors (TLR's) (e.g. TLR 3 and 7/8) or by TLR-independent intracellular DExD/H box RNA helicases referred to as retinoic acid inducible gene 1 (RIG-I) or melanoma differentiation associated antigen 5 (MDA5, also referred to as IFIH1 and helicard). These events culminate in the activation of downstream signaling events, much of which remains unknown, leading to the transcription of NF-κΒ and IRF3/7- dependent genes, including type I IFN.
[0005] The generation of T cells that recognize specific antigens presented on tumor cells constitutes an important host defense response that has evolved to eliminate the development of cancer (1). The mechanisms underlining the stimulation of antigen presenting cells (APC) and the priming of tumor specific T cells remains to be clarified but is thought to involve the generation of immuno stimulatory type I interferon (IFN) and other cytokines triggered by DNA
from the engulfed cell (2-6). The innate immune pathways governing these events involve STING (stimulator of interferon genes) signaling within phagocytes such as CD8+ dendritic cells (7-10). STING recognizes cyclic dinucleotides including c-di-GMP or c-di-AMP secreted by intracellular bacteria or cyclic-GMP-AMP (cGAMP) generated by the cellular synthase Cyclic GMP-AMP synthase (cGAS) following association with cytosolic dsDNA species (11, 12). Generally, non-tumorigenic cells undergoing apoptosis avoid activating APC's, an event that would otherwise cause lethal autoinflammatory disease due to chronic cytokine production (13- 15), by likely adopting comparable processes, tumor cells are also able to avoid the activation of APC's and thus the subsequent spontaneous generation of T-cells. In contrast, microbial infected cells are potently able to activate APCs following engulfment, and can robustly generate anti-pathogen T-cells (16, 17). While DNA from engulfed cells is known to play a key role in stimulating APC's (18), how phagocytes differentiate between an apoptotic/tumorigenic cell and an infected cell, both of which harbor considerable amounts of cellular DNA, remains to be fully determined.
SUMMARY OF THE DISCLOSURE
[0006] The present disclosure demonstrates that dsDNA having a structure sufficient to stimulate an immune response is useful to activate STING (STimulator of INterferon Genes) and has an effect at stimulating immune response in vivo, suggesting the STING activators will be useful in the treatment of autoimmune disease, infection and cancer..
[0007] The disclosure provides an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
[0008] In various embodiments, the dsDNA is approximately 30 nucleotides in length. In various embodiments the dsDNA is approximately 70 nucleotides in length. It is contemplated that the STING activator dsDNA can be 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90 nucleotides in length.
[0009] In various embodiments, the dsDNA is AT rich or GC rich. In various embodiments, the activator sequence may consist of all A residues, all T residues, alternating A and T residues, or a mixture of A and T residues, e.g., wherein 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are A residues or T residues, and the remaining residues are the complementary
nucleotide. It is also contemplated that the activator sequence may consist of all G residues, all C residues, alternating G and C residues, or a mixture of G and C residues, e.g., wherein 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are G residues or C residues, and the remaining residues are the complementary nucleotide. Further, the activator polynucleotide may be a mixture of A, T, G and C nucleotides.
[0010] In various embodiments, the 5' end and/or the 3' end of the activator polynucleotide is modified. In some embodiments, the 5' end is modified by phosphorothioate linkage. In some embodiments, the 3' end is modified by phosphorothioate linkage. In some embodiments, the first three nucleotides at the 5' end are modified by phosphorothioate linkage. In some embodiments, the last three nucleotides at the 3' end are modified by phosphorothioate linkage. In various embodiments, the activator nucleotide is modified every 2, 3, 4, or 5 nucleotides. In various embodiments, the activator nucleotide is modified at every third base.
wherein the first three and last three nucleotides are modified by phosphorothioate linkage;
last three nucleotides are modified by phosphorothioate linkage.
[0013] Also contemplated by the disclosure is a composition comprising a STING activator as described herein and a pharmaceutically acceptable carrier. In various embodiments, the composition is a sterile composition.
[0014] Further provided by the disclosure is a vector comprising a STING activator as described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
[0015] Also provided is a vaccine comprising a STING activator as described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
[0016] In various embodiments, the nucleotide is in a vector. In various embodiments, the vector is a viral or a plasmid vector. In one embodiment, the viral vector is selected from the group consisting of vesicular stomatitis virus (VSV), a lentivirus, an acdenovirus, an adeno- associated virus, a vaccinia virus and a modified vaccinia Ankara (MVA) virus.
[0017] The disclosure also contemplates a method of activating STING in a subject in need thereof comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
[0018] Provided herein is a method of stimulating an immune response in a subject in need thereof comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) as described herein comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
[0019] In various embodiments, the subject is suffering from cancer or a microbial infection. Exemplary cancers and microbial infections contemplated herein are described further in the Detailed Description.
[0020] The disclosure contemplates a method of decreasing the size of a tumor in a subject comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
[0021] Also provided is a method of treating cancer in a subject comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
[0022] In various embodiments, the cancer is ovarian cancer, colon cancer, melanoma, breast cancer or lung cancer.
[0023] In various embodiments, tumor size in the subject is decreased by about 25-50%, about 40-70% or about 50-90% or more.
[0024] In various embodiments, the STING activator is administered intratumorally, intravenously, intra-arterially, intraperitoneally, intranasally, intramuscularly, intradermally or subcutaneously.
[0025] In various embodiments, the STING activator induces infiltration of immune cells into the tumor. In various embodiments, the immune cells are macrophages or other phagocytes.
[0026] In various embodiments, the STING activator oligonucleotide remains cytosolic in a cell. In various embodiments, the STING activator induces CxcllO and/or type I IFN cytokine production.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Fig. 1A-1J. Various STING ligands with different sequences and polynucleotide length. (Figure 1A-1C): different sequence, (Figure 1D-1F) : different length of AT rich ligands, (Figure 1G-I): different length of GC rich ligands (Figure 1G-1I). IFNb ELISA assay of MEFs (Figure 1A, ID, 1G) and hTERT (Figure IB, IE, 1H). IFNb ELISA assay (Figure 1C) and qPCR of IFNb (Figure IF- II) in primary human macrophages treated with 3ug/ml of STING ligands. (Figure 1J) Evaluation of DNA amount in B 16 OVA cells transfected with 3 ug of STAV.
[0028] Fig. 2A-2L. Activation of macrophages by exogenous cytosolic DNA (STAVs) in engulfed apoptotic cells. (Figure 2A) Confocal analysis and flow cytometry analysis of B 16 OVA cells (B 16) transfected with FAM labeled STAVs (green). DAPI (blue) and anti- Calreticulin (red) as counter staining. (Figure 2B) Gene array analysis of B 16 cells transfected with STAVs. Highest variable inflammation-related genes are shown. (Figure 2C) qPCR analysis of Ιίηβ, CxcllO and Ifit3 in B 16 OVA cells same as in (Figure 2B). (Figure 2D) Western blot analysis of STING, p65 and IRF3 in B 16 cells transfected with STAVs at following time points. (Figure 2E) Immunofluorescent analysis using anti-STING and anti-p65 in B 16 cells at 3 hours after transfection of STAVs. (Figure 2F) Schematic representation of the phagocytosis of B 16 cells by macrophages. B 16 cells were transfected by STAVs for 3 hours and irradiated by UV (120mJ/cm). The irradiated B 16 cells were feed to macrophages (M0) at 24 hours after UV irradiation. (Figure 2G) Confocal analysis and (Figure 2H) Flow cytometry analysis in macrophages following cellular engulfment of B 16 cells transfected with FAM labeled STAVs.
qPCR analysis of CxcllO (Figure 21) and IFN (Figure 2J) in wild type (WT) and sting knock out (SKO) macrophages (WT M0 and SKO M0) following engulfment of B 16 cells
with/without STAVs. Flow cytometry for CD86 (Figure 2K) and H2Kb (Figure 2L) on macrophages following phagocytosis of B 16 cells. Data is representative of at least three independent experiments. Error bars indicate s.d. *; p<0.05, Student's t-test.
[0029] Fig. 3A-3D. B16 OVA cells to feed to macrophages. B 16 OVA cells were transfected with 3 ug/ml of ISD-FITC for 24 hours and 48 hours. (Figure 3A) Flow cytometry analysis of B 16 OVA cells stained with propidium iodide and annexin V. (Figure 3B) Flow cytometry analysis for residual FITC-labelled DNA in B 16 OVA cells following UV irradiation. (Figure 3c) Western blot analysis using anti-OVA in B 16 OVA cells following UV irradiation. Beta actin was used as control. (Figure 3D) Flow cytometry analysis in macrophages following cellular engulfment of CFSE labelled B 16 OVA cells.
[0030] Fig. 4A-4D. Extrinsic STING signaling dependent gene expression in
macrophages. (Figure 4A) Flow cytometry analysis in macrophages following cellular engulfment of HEK293 cells (293) transfected with FAM labeled STAVs. (Figure 4B) Gene array analysis of WT and SKO macrophages following engulfment of irradiated 293 cells with/without STAVs. Highest variable inflammation-related genes are shown. qPCR analysis of CxcllO (Figure 4C) and IFN (Figure 4D) in same as in (Figure 4A). Data is representative of at least three independent experiments. Error bars indicate s.d. *; p<0.05, Student's t-test.
[0031] Fig. 5A-5H. Macrophage stimulation in trans by cytosolic DNA. (Figure 5A) Western blot analysis of STING and cGAS in mouse embryonic fibroblasts (MEFs). (Figure 5B) ELISA of IFN in WT, SKO and cGAS knock out (cGAS KO) transfected with STAVs. (Figure 5C) Schematic representation of the phagocytosis of MEFs by macrophages. qPCR analysis of CxcllO (Figure 5D) and IFN (Figure 5E) in WT and SKO macrophages following engulfment of UV irradiated WT, SKO and cGAS KO MEFs with STAVs. (Figure 5F) ELISA of IFN in 293T and hTERT cells transfected with STAVs. qPCR analysis of CxcllO (Figure 5G) and IFN (Figure 5H) in WT and SKO macrophages following engulfment of UV irradiated 293T cells with or without STAVs. Data is representative of at least three independent experiments. Error bars indicate s.d. *; p<0.05, Student's t-test.
[0032] Fig. 6A-6F. Extrinsic activation of the cGAS/STING axis in macrophages. (Figure 6A) qPCR analysis of CxcllO and IFN in WT, SKO, cGAS KO and TLR9 KO macrophages following engulfment of STAVs treated B 16 cells. (Figure 6B) cGAS expression by Western blot and cGAMP amount by a hybrid mass spectrometer. (Figure 6C) qPCR analysis of CxcllO in WT, SKO, and cGAS KO macrophages following engulfment of 293T cells containing STAVs. The 293T cells were reconstituted with pcGAS or pCMV as control vector. (Figure 6D) Measurement of cGAMP levels by a hybrid mass spectrometer in 293T cells same as in (C). (Figure 6E) qPCR analysis of CxcllO in WT, SKO, and cGAS KO macrophages following engulfment of HTl 16 cells containing STAVs. The HTl 16 cells were reconstituted with pcGAS or pCMV as control vector. (Figure 6F) qPCR analysis of IFN in WT, SKO, cGAS KO, and Trexl KO macrophages following engulfment of B 16 cells infected with HSVy34.5. The HTl 16 cells were reconstituted with pcGAS or pCMV as control vector. Error bars indicate s.d. *; p<0.05, Student's t-test.
[0033] Fig. 7A-7C. Activation of antigen presenting cells by STAVs. WT, SKO, cGAS KO macrophages were transfected with 3 ug/ml of (Figure 7A) AT90ES or (Figure 7B) cGAMP and (Figure 7C) Ifnb treatment for 24 hours followed by pulsing with or without SIINFEKL. Antigen presentation was evaluated by flow cytometry analysis using antibody reacting with OVA peptide SIINFEKL bound to H-2Kb of MHC class I.
[0034] Fig. 8A-8D. Apoptotic cells containing STAVs escape degradation by DNase II.
(Figure 8A) Schematic representation of the phagocytosis of B 16 cells by DNase I, DNase II, or Trexl Knockout macrophages. B 16 cells were transfected by STAVs for 3 hours and irradiated by UV (120mJ/cm). The irradiated B 16 cells were feed to three different genotypes of macrophages (M0) at 24 hours after UV irradiation. qPCR analysis of CxcllO in (Figure 8B) DNase I KO, (Figure 8C) DNase II KO and (Figure 8D) Trexl KO macrophages at 6 hrs following engulfment of B 16 cells containing STAVs. Error bars indicate s.d. *; p<0.05, Student's t-test.
[0035] Fig. 9A-9D. Anti-tumor activity of STAVs in B16 OVA melanomas. (Figure 9A) Schematic representation of intratumoral injection of STAVs in B 16 OVA melanoma. The mice were subcutaneously injected with B 16-OVA cells on the flank. lOug of STAVs was injected intratumorally (i.t.) every three days. Tumor volumes from (Figure 9B) WT (n=7/group) and
(Figure 9C) SKO mice (n=7/group) were measured on the indicated days. (Figure 9D) Frequency of OVA specific CD8+ T cells in the spleen from WT (n=4/group) and SKO (n=4/group) mice injected with STAV or PBS as control. Error bars indicate s.d. *; p<0.05, Student's t-test.
[0036] Fig. 10A-10G. Protection of lung metastasis by B16 OVA requires STING.
(Figure 10A) Schematic representation of the dead cell immunization. B16 OVA cells were transfected by STAVs for 3 hours and irradiated by UV (120mJ/cm). After 24 hours, WT, SKO, TLR9 KO, and cGAS KO mice were i.p. injected with the irradiated B16 cells with/without STAV, twice every week. (Figure 10B) LFNy measurement in splenocytes from WT, SKO, TLR9 KO, and cGAS KO mice at 7 days after the second immunization. (Figure IOC) Schematic representation of post-vaccination for B16 OVA mediated lung metastasis. WT, TLR9KO, SKO, and cGAS KO mice were IV. injected with B16 OVA cells. On day 1, 3, 7, and 14, the mice were LP injected by UV irradiated B 16 OVA cells (1X105 cells/mouse) with STAVs. Survival rates from (Figure 10D) WT (p=0.0429, n=7/group), (Figure 10E) SKO (p=0.2616, n=7/group), (Figure 10F) cGAS KO (p=0.4075,n=7/group), and (Figure 10G) TLR9KO (p=0.0012 n=7/group) mice were monitored. P values are based on Logrank test, with P<0.05 considered statistically significant.
[0037] Fig. 11. Fold changes of gene array analysis in B16 cells transfected with
STAVs. Gene expression fold changes of ILLUMLNA array of B16 cells transfected with STAVs. Fold change analysis was performed between two groups and differentially expressed genes were selected based on threshold of Fold change > 3 from a comparison between untransfected and STAVs transfected B16 cells.
[0038] Fig. 12. Fold changes of gene array analysis in B16 feeding macrophages.
Gene expression fold changes of ILLUMLNA array.
DETAILED DESCRIPTION
[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton, et al., DICTIONARY OF MICROBIOLOGY AND
8
RECTIFIED (RULE 91) - ISA/US
MOLECULAR BIOLOGY (2d ed. 1994); THE CAMBRIDGE DICTIONARY OF SCIENCE AND TECHNOLOGY (Walker ed., 1988); THE GLOSSARY OF GENETICS, 5TH ED., R. Rieger, et al. (eds.), Springer Verlag (1991); and Hale and Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY (1991).
[0040] Each publication, patent application, patent, and other reference cited herein is incorporated by reference in its entirety to the extent that it is not inconsistent with the present disclosure.
[0041] It is noted here that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.
[0042] As used herein, the following terms have the meanings ascribed to them unless specified otherwise.
Definitions
[0043] The term "induces or enhances an immune response" as used herein refers to causing a statistically measurable induction or increase in an immune response over a control sample to which the peptide, polypeptide or protein has not been administered. Preferably the induction or enhancement of the immune response results in a prophylactic or therapeutic response in a subject. Examples of immune responses are increased production of type I IFN, increased resistance to viral and other types of infection by alternate pathogens. The enhancement of immune responses to tumors (anti-tumor responses), or the development of vaccines to prevent tumors or eliminate existing tumors.
[0044] The term "STING" as used herein includes, without limitation, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands, complementary sequences, peptides, polypeptides, proteins, homologous and/or orthologous STING molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.
[0045] A "STING activator" or "STAV" as used herein refers to a nucleotide that when introduced into or produced by a cell can induce signaling through the STING protein. In nature, cyclic dinucleotides (CDN) are natural activators of STING, but are not often induced in tumor cells, or are used by tumor cells to evade tumor cell death. It is contemplated herein that the
STAV is a double standard DNA molecule that when introduced into the cytosol of a cell activates STING signaling. The STAV dsDNA may have a modified 5' end and/or may have modified bases every 2, 3, 4 or 5 nucleotides throughout the nucleotide sequences. In various embodiments, the STAV is about 20 to 90, 25 to 90, or 30 to 70 nucleotides in length, or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90 nucleotides in length.
[0046] A "DNA Vaccine" or "DNA vector" as used herein refers to a synthetic DNA structure that can be transcribed in target cells and can comprise a linear nucleic acid such as a purified DNA, a DNA incorporated in a plasmid vector, or a DNA incorporated into any other vector suitable for introducing DNA into a host cell. In various embodiments, the DNA vaccine can be naked DNA. Provided herein is a naked DNA vaccine, a plasmid DNA vaccine or a viral vector vaccine. It is contemplated that the vaccine is a live viral vaccine, live attenuated viral vaccine, or inactivated or killed viral vaccine. In various embodiments, the vaccine may comprise viruslike particles (VLPs).
[0047] "Vesicular stomatitis virus" or " VSV" as used herein refers to any strain of VSV or mutant forms of VSV, such as those described in WO 01/19380 or US20140088177. A VSV construct herein may be in any of several forms, including, but not limited to, genomic RNA, mPvNA, cDNA, part or all of the VSV RNA encapsulated in the nucleocapsid core, VSV complexed with compounds such as PEG and VSV conjugated to a nonviral protein. VSV vectors useful herein encompass replication-competent and replication-defective VSV vectors, such as, VSV vectors lacking G glycoprotein.
[0048] As used herein, the term "vector" refers to a polynucleotide construct designed for transduction/transfection of one or more cell types. VSV vectors may be, for example, "cloning vectors" which are designed for isolation, propagation and replication of inserted nucleotides, "expression vectors" which are designed for expression of a nucleotide sequence in a host cell, or a "viral vector" which is designed to result in the production of a recombinant virus or virus-like particle, or "shuttle vectors", which comprise the attributes of more than one type of vector. The present invention encompasses viral vectors, such as vesicular stomatitis virus (VSV), a lentivirus, an acdenovirus, an adeno-associated virus, a vaccinia virus, or a modified vaccinia Ankara (MVA) virus vectors that comprise nucleic acid encoding Zika virus proteins, such as an Env protein. It is contemplated that the vectors can comprises a polynucleotide encoding a Zika
protein as well as a polynucleotide encoding another protein that may improve efficacy of the vector, such as cytokines, including but not limited to those cytokines described herein;
chemokines, such as for example, Mip; co- stimulatory proteins, such as for example, B7-1 and B7-2; angiostatin; endostatin; and heat shock proteins, such as for example gp96.
[0049] The terms "polynucleotide" and "nucleic acid", used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple- stranded DNA, genomic DNA, cDNA, genomic RNA, mRNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. Alternatively, the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidates and thus can be a oligodeoxynucleoside phosphoramidate (P-NH2) or a mixed phosphoramidate-phosphodiester oligomer. Peyrottes et al. (1996) Nucleic Acids Res. 24: 1841- 8; Chaturvedi et al. (1996) Nucleic Acids Res. 24: 2318-23; Schultz et al. (1996) Nucleic Acids Res. 24: 2966-73. A phosphorothioate linkage can be used in place of a phosphodiester linkage. Braun et al. (1988) J. Immunol. 141: 2084-9; Latimer et al. (1995) Molec. Immunol. 32: 1057- 1064. In addition, a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer. Reference to a
polynucleotide sequence (such as referring to a SEQ ID NO) also includes the complement sequence.
[0050] The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, genomic RNA, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support.
[0051] "Encoding" refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and non-coding strand, used as the template for transcription, of a gene or cDNA can be referred to as encoding the protein or other product of that gene or cDNA. Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.
[0052] "Under transcriptional control" is a term well understood in the art and indicates that transcription of a polynucleotide sequence depends on its being operably (operatively) linked to an element which contributes to the initiation of, or promotes, transcription. "Operably linked" refers to a juxtaposition wherein the elements are in an arrangement allowing them to function.
[0053] As used herein, in the context of the viral vectors , a "heterologous polynucleotide" or "heterologous gene" or "transgene" is any polynucleotide or gene that is not present in wild-type viral vector.
[0054] As used herein, in the context of the vectors, a "heterologous" promoter is one which is not associated with or derived from the vector itself.
[0055] A "host cell" includes an individual cell or cell culture which can be or has been a recipient of a vector(s) described herein. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA
complement) to the original parent cell due to natural, accidental, or deliberate mutation and/or
change. A host cell includes cells transfected, transformed or infected in vivo or in vitro with a vector herein.
[0056] A "vector" (sometimes referred to as gene delivery or gene transfer "vehicle") refers to a macromolecule or complex of molecules comprising a polynucleotide to be delivered to a host cell, either in vitro or in vivo. The polynucleotide to be delivered may comprise a coding sequence of interest in gene therapy. Vectors include, for example, viral vectors (such as adenoviruses ("Ad"), adeno-associated viruses (AAV), and vesicular stomatitis virus (VSV) and retroviruses), liposomes and other lipid-containing complexes, and other macromolecular complexes capable of mediating delivery of a polynucleotide to a host cell. Vectors can also comprise other components or functionalities that further modulate gene delivery and/or gene expression, or that otherwise provide beneficial properties to the targeted cells. As described and illustrated in more detail below, such other components include, for example, components that influence binding or targeting to cells (including components that mediate cell-type or tissue- specific binding); components that influence uptake of the vector nucleic acid by the cell;
components that influence localization of the polynucleotide within the cell after uptake (such as agents mediating nuclear localization); and components that influence expression of the polynucleotide. Such components also might include markers, such as detectable and/or selectable markers that can be used to detect or select for cells that have taken up and are expressing the nucleic acid delivered by the vector. Such components can be provided as a natural feature of the vector (such as the use of certain viral vectors which have components or functionalities mediating binding and uptake), or vectors can be modified to provide such functionalities. Other vectors include those described by Chen et al; BioTechniques, 34: 167- 171 (2003). A large variety of such vectors are known in the art and are generally available.
[0057] The term "expression vector" as used herein refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules, siRNA, ribozymes, and the like. Expression vectors can contain a variety of control sequences, which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operatively linked coding sequence in a particular host organism. In addition to control
sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well.
[0058] As used herein, "vaccine" refers to a composition comprising a vector comprising a STING activator as described herein, which is useful in the treatment of cancer or other conditions in which enhanced immune response is indicated. It is contemplated that the vaccine comprises a pharmaceutically acceptable carrier and/or an adjuvant. It is contemplated that vaccines are prophylactic or therapeutic. A "prophylactic" treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs for the purpose of decreasing the risk of developing pathology. The compounds of the invention may be given as a prophylactic treatment to reduce the likelihood of developing a pathology or to minimize the severity of the pathology, if developed. A "therapeutic" treatment is a treatment administered to a subject who exhibits signs or symptoms of pathology for the purpose of diminishing or eliminating those signs or symptoms. The signs or symptoms may be biochemical, cellular, histological, functional, subjective or objective.
[0059] "An antigen presenting cell" (APC) is a cell that is capable of activating T cells, and includes, but is not limited to, monocytes/macrophages, B cells and dendritic cells (DCs). The term "dendritic cell" or "DC" refers to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. These cells are characterized by their distinctive morphology, high levels of surface MHC-class II expression. DCs can be isolated from a number of tissue sources. DCs have a high capacity for sensitizing MHC- restricted T cells and are very effective at presenting antigens to T cells in situ. The antigens may be self-antigens that are expressed during T cell development and tolerance, and foreign antigens that are present during normal immune processes.
[0060] The "treatment of cancer", refers to one or more of the following effects: (1) inhibition, to some extent, of tumor growth, including, (i) slowing down and (ii) complete growth arrest; (2) reduction in the number of tumor cells; (3) maintaining tumor size; (4) reduction in tumor size; (5) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of tumor cell infiltration into peripheral organs; (6) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of metastasis; (7) enhancement of anti-tumor immune response, which may result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing the growth
of a tumor, (iv) reducing, slowing or preventing invasion and/or (8) relief, to some extent, of the severity or number of one or more symptoms associated with the disorder.
[0061] As used herein, "isolated" refers to a polynucleotide, virus or antigenic composition that is removed from its native environment. Thus, an isolated biological material is free of some or all cellular components, i.e., components of the cells in which the native material occurs naturally (e.g., cytoplasmic or membrane component). In one aspect, a polynucleotide, virus or antigenic composition is deemed isolated if it is present in a cell extract or supernatant. In the case of nucleic acid molecules, an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment.
[0062] "Purified" as used herein refers to a virus or immunogenic composition that has been isolated under conditions that reduce or eliminate the presence of unrelated materials, i.e., contaminants, including endogenous materials from which the composition is obtained. By way of example, and without limitation, a purified virion is substantially free of host cell or culture components, including tissue culture or cell proteins and non-specific pathogens. In various embodiments, purified material substantially free of contaminants is at least 50% pure; at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or even at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.
[0063] As used herein, "pharmaceutical composition" refers to a composition suitable for administration to a subject animal, including humans and mammals. A pharmaceutical composition comprises a pharmacologically effective amount of a virus or antigenic composition of the invention and also comprises a pharmaceutically acceptable carrier. A pharmaceutical composition encompasses a composition comprising the active ingredient(s), and the inert ingredient(s) that make up the pharmaceutically acceptable carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound or conjugate of the present invention and a pharmaceutically acceptable carrier.
[0064] As used herein, "pharmaceutically acceptable carrier" include any and all clinically useful solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and
absorption delaying agents, buffers, and excipients, such as a phosphate buffered saline solution, 5% aqueous solution of dextrose or mannitol, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents and/or adjuvants. Suitable pharmaceutical carriers and formulations are described in Remington's Pharmaceutical Sciences, 19th Ed. (Mack
Publishing Co., Easton, 1995). Pharmaceutical carriers useful for the composition depend upon the intended mode of administration of the active agent. Typical modes of administration include, but are not limited to, enteral (e.g. , oral) or parenteral (e.g. , subcutaneous, intramuscular, intravenous or intraperitoneal injection; or topical, transdermal, or transmucosal administration). A "pharmaceutically acceptable salt" is a salt that can be formulated into a compound or conjugate for pharmaceutical use including, e.g. , metal salts (sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.
[0065] As used herein, "pharmaceutically acceptable" or "pharmacologically acceptable" refers to a material which is not biologically or otherwise undesirable, i.e. , the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained, or when administered using routes well-known in the art, as described below.
[0066] As used herein, a "condition" or "disorder" associated with a "target" in which modification of target activity described herein is beneficial and also includes other disorders in which high levels of target have been shown to be or are suspected of being either responsible for the pathophysiology of the disorder or a factor that contributes to a worsening of the disorder, as well as diseases and other disorders in which modulation of the target is associated with changes in clinical signs or symptoms. Such disorders may be evidenced, for example, by an increase in the levels of target secreted and/or on the cell surface and/or modified target signaling in the affected cells or tissues of a subject suffering from the disorder. Exemplary diseases, conditions or disorders that can be treated with a STING activator are described in more detail in the Detailed Description.
STING (Stimulator of Interferon Genes)
[0067] STING (Stimulator of Interferon Genes), a molecule that plays a key role in the innate immune response, includes 5 putative transmembrane (TM) regions, predominantly resides in the endoplasmic reticulum (ER), and is able to activate both NF-κΒ and IRF3 transcription pathways
to induce type I IFN and to exert a potent anti- viral state following expression. Human STING is a 379 amino acid protein, having an amino acid sequence set out in Genbank Accession No. NP_938023 and nucleotide sequence set out in Genbank Accession No. NM_198282, though alternate protein isoforms may exist (Genbank Accession Nos. NP_001288667.1,
XP_011535942.1, XP 011535941.1). See e.g., U.S. patent publication 20130039933 and PCT/US2009/052767, herein incorporated by reference in their entirety. The amino acid sequence of human STING (379 amino acids) is set out below (SEQ ID NO: 3): M P H S S L H
P S I P C P R G H G A Q K A A L V L L S A C L V T L W G L G E P P E H T L R Y L V L H L A S L Q L G L L L N G V C S L A E E L R H I H S R Y R G S Y W R T V R A C L G C P L R R G A L L L L S I Y F Y Y S L P N A V G P P F T W M L A L L G L S Q A L N I L L G L K G L A P A E I S A V C E K G N F N V A H G L A W S Y Y I G Y L R L I L P E L Q A R I R T Y N Q H Y N N L L R G A V S Q R L Y I L L P L D C G V P D N L S M A D P N I R F L D K L P Q Q T G D H A G I K D R V Y S N S I Y E L L E N G Q R A G T C V L E Y A T P L Q T L F A M S Q Y S Q A G F S R E D R L E Q A K L F C R T L E D I L A D A P E S Q N N C R L I A Y Q E P A D D S S F S L S Q E V L R H L R Q E E K E E V T V G S L K T S A V P S T S T M S Q E P E L L I S G M E K P L P L R T D F S.
[0068] Loss of STING reduced the ability of polyLC to activate type I IFN and rendered murine embryonic fibroblasts lacking STING (_/~ MEFs) generated by targeted homologous recombination, susceptible to vesicular stomatitis virus (VSV) infection. In the absence of STING, DNA-mediated type I IFN responses were inhibited, indicating that STING may play an important role in recognizing DNA from viruses, bacteria, and other pathogens which can infect cells. Yeast-two hybrid and co-immunoprecipitation studies indicated that STING interacts with RIG-I and with Ssr2/TRAPp, a member of the translocon-associated protein (TRAP) complex required for protein translocation across the ER membrane following translation. RNAi ablation of TRAPP inhibited STING function and impeded the production of type I IFN in response to polylC.
[0069] Further experiments showed that STING itself binds nucleic acids including single- and double- stranded DNA such as from pathogens and apoptotic DNA, and plays a central role in regulating proinflammatory gene expression in inflammatory conditions such as DNA- mediated arthritis and cancer. Certain inhibitors and activators of STING are discussed in International Patent Publication No. WO 2013/166000.
STING Activators
[0070] In nature, cyclic dinucleotides (CDN) are natural activators of STING, but are not often induced in tumor cells, or are used by tumor cells to evade tumor cell death. CDNs typically stay in the nucleus and are not leaked into the cytosol, which helps tumors evade immune cells. In order to use the advantages of STING in cancer, the inventors developed a nucleotide that could stay in the cytosol and induce STING activation in response to free dsDNA, similar to the situation in apoptosis of a cell.
[0071] It is contemplated herein that the STAV is a double stranded DNA molecule that when introduced into the cytosol of a cell activates STING signaling.
[0072] In various embodiments, the STAV is about 20 to 90, 25 to 90, or 30 to 70 nucleotides in length, or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90 nucleotides in length.
[0073] In various embodiments, the activator oligonucleotide herein is AT (adenine-thymine) rich or GC (guanine-cytosine) rich. For example, the activator sequence may consist of all A residues, all T residues, alternating A and T residues, or a mixture of A and T residues, e.g., wherein approximately 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are A residues or T residues, and the remaining residues are the complementary nucleotide. It is also contemplated that the activator sequence may consist of all G residues, all C residues, alternating G and C residues, or a mixture of G and C residues, e.g., wherein approximately 20, 30, 40, 50, 60, 70, 80 or 90% or more of the nucleotides are G residues or C residues, and the remaining residues are the complementary nucleotide. Further, the activator polynucleotide may be a mixture of A, T, G and C nucleotides. In various embodiments, the activator has a sequence as follows: Sense strand:
wherein the first three and last three nucleotides are modified by phosphorothioate linkage; 0074 Anti-Sense strand:
last three nucleotides are modified by phosphorothioate linkage.
[0075] The STAV dsDNA may have a modified 5' end and/or may have modified bases every 2, 3, 4 or 5 nucleotides throughout the nucleotide sequences. The 5' end and/or 3' end may be modified. In some embodiments, the 5' end is modified by phosphorothioate linkage. In some embodiments, the 3' end is modified by phosphorothioate linkage. In some embodiments, the first three nucleotides at the 5' end are modified by phosphorothioate linkage. In some embodiments, the last three nucleotides at the 3' end are modified by phosphorothioate linkage. In various embodiments, the activator nucleotide is modified every 2, 3, 4, or 5 nucleotides. In various embodiments, the activator nucleotide is modified at every third base.
[0076] In one embodiment, a STAV oligonucleotide may comprise combinations of phosphorothioate internucleotide linkages and at least one internucleotide linkage selected from the group consisting of: alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and/or combinations thereof.
[0077] In another embodiment, a STAV oligonucleotide optionally comprises at least one modified nucleobase comprising, peptide nucleic acids, locked nucleic acid (LNA) molecules, analogues, derivatives and/or combinations thereof.
[0078] Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein,
"unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2' deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2- (imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7- deazaguanine, N.sub.6 (6-aminohexyl)adenine and 2,6-diaminopurine. Kornberg, A., DNA Replication, W. H. Freeman & Co., San Francisco, 1980, pp 75-77; Gebeyehu, G., et al. Nucl. Acids Res. 1987, 15:4513). A "universal" base known in the art, e.g., inosine, may be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-
1.2. degree. C. (Sanghvi, Y. S., in Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions.
[0079] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA 1989, 86, 6553), cholic acid (Manoharan et al. Bioorg. Med. Chem. Let. 1994, 4, 1053), a thioether, e.g., hexyl-5-tritylthiol (Manoharan et al. Ann. N.Y. Acad. Sci. 1992, 660, 306;
Manoharan et al. Bioorg. Med. Chem. Let. 1993, 3, 2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res. 1992, 20, 533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al. EMBO J. 1991, 10, 111; Kabanov et al. FEBS Lett. 1990, 259, 327; Svinarchuk et al. Biochimie 1993, 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium l,2-di-0-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.
Tetrahedron Lett. 1995, 36, 3651; Shea et al. Nucl. Acids Res. 1990, 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan et al. Nucleosides & Nucleotides 1995, 14, 969), or adamantane acetic acid (Manoharan et al. Tetrahedron Lett. 1995, 36, 3651). Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides are known in the art, for example, U.S. Pat. Nos. 5,138,045, 5,218,105 and 5,459,255.
[0080] It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide. The present invention also includes oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.
[0081] In another embodiment, the nucleic acid molecule of the present invention is conjugated with another moiety including but not limited to abasic nucleotides, polyether, polyamine, polyamides, peptides, carbohydrates, lipid, or polyhydrocarbon compounds. Those skilled in the art will recognize that these molecules can be linked to one or more of any nucleotides comprising the nucleic acid molecule at several positions on the sugar, base or phosphate group.
[0082] In accordance with the disclosure, use of modifications such as the use of LNA monomers to enhance the potency, specificity and duration of action and broaden the routes of administration of oligonucleotides comprised of current chemistries such as MOE, ANA, FANA, PS etc. (ref: Recent advances in the medical chemistry of antisense oligonucleotide by Uhlman, Current Opinions in Drug Discovery & Development 2000 Vol 3 No 2). This can be achieved by substituting some of the monomers in the current oligonucleotides by LNA monomers. The LNA modified oligonucleotide may have a size similar to the parent compound or may be larger or preferably smaller. It is preferred that such LNA-modified oligonucleotides contain less than about 70%, more preferably less than about 60%, most preferably less than about 50% LNA monomers and that their sizes are between about 5 and 25 nucleotides, more preferably between about 12 and 20 nucleotides.
[0083] Preferred modified oligonucleotide backbones comprise, but not limited to,
phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters,
aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3' alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates,
thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'- 5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.
[0084] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane
backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts.
[0085] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
[0086] In another preferred embodiment of the invention the oligonucleotides with
phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular- CH2-NH-O-CH2-, --CH2--N(CH3)--0--CH2-known as a methylene (methylimino) or MMI backbone, -CH2-0-N(CH3)-CH2-, -CH2N(CH3)-N(CH3)CH2-and-0--N(CH3)-CH2— CH2- - wherein the native phosphodiester backbone is represented as— O— P— O— CH2— of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.
[0087] Modified oligonucleotides may also contain one or more substituted sugar moieties.
Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; 0-, S-, or N- alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or O alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C to CO alkyl or C2 to CO alkenyl and alkynyl.
Particularly preferred are O (CH2). On,CH3, 0(CH2)„,OCH3, 0(CH2)nNH2, 0(CH2)nCH3,
0(CH2)nONH2, and 0(CH2nON(CH2)nCH3)2 where n and m can be from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C to CO, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, CI, Br,
CN, CF3, OCF3, SOCH3, S02CH3, ON02, N02, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification comprises 2'-methoxyethoxy
(2'-0-CH2CH2OCH3, also known as 2'-0-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv.
Chim. Acta, 1995,78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification
comprises 2'-dimethylaminooxyethoxy, i.e., a 0(CH2)20N(CH3)2 group, also known as 2'- DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-0-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-0-CH2-0-CH2- N(CH2)2.
[0088] Other preferred modifications comprise 2'-methoxy (2'-0 CH3), 2'-aminopropoxy (2'- OCH2CH2CH2NH2) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide.
Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
[0089] Oligonucleotides may also comprise nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2- propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2- thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8- hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5- trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7- methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3- deazaguanine and 3-deazaadenine.
[0090] Further, nucleobases comprise those disclosed in "The Concise Encyclopedia of Polymer Science And Engineering", pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., "Angewandle Chemie, International Edition", 1991, 30, page 613, and those disclosed by Sanghvi, Y. S., Chapter 15, "Antisense Research and
Applications", pages 289-302, Crooke, S. T. and Lebleu, B. ea., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These comprise 5-substituted pyrimidines, 6-azapyrimidines and
N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5- propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds, Antisense Research and Applications", CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-0-methoxyethyl sugar modifications.
Methods of Use
[0091] In various embodiments, the disclosure provides a method of activating STING in a subject in need thereof comprising administering a composition comprising an activator of STING described herein, wherein the activator induces STING signaling.
[0092] Further contemplated is a method of stimulating an immune response in a subject in need thereof comprising administering a composition comprising an activator of STING described herein. In various embodiments, the immune response is an ongoing immune response in cancer, a microbial infection or an autoimmune disease. In various embodiments, the STING activator may be administered prophylactically in a disease or disorder in which an immune response is in a remission phase, e.g., in cancer or an autoimmune disease.
[0093] In one embodiment, the disclosure provides a method of decreasing the size of a tumor in a subject having a tumor or cancer comprising administering a composition comprising an activator of STING. Also provided is a method for treating cancer or preventing the recurrence of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a STAV or a pharmaceutical composition comprising a STAV or vector or vaccine comprising a STAV as described herein.
[0094] Exemplary conditions or disorders that can be treated with STAVs include cancers, such as esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic
adenocarcinoma of the pancreas, bladder cancer, stomach cancer, fibrotic cancer, glioma, malignant glioma, diffuse intrinsic pontine glioma, recurrent childhood brain neoplasm renal cell carcinoma, clear-cell metastatic renal cell carcinoma, kidney cancer, prostate cancer, metastatic castration resistant prostate cancer, stage IV prostate cancer, metastatic melanoma, melanoma, malignant melanoma, recurrent melanoma of the skin, melanoma brain metastases, stage IDA skin melanoma; stage MB skin melanoma, stage IIIC skin melanoma; stage IV skin melanoma,
malignant melanoma of head and neck, lung cancer, non-small cell lung cancer (NSCLC), squamous cell non-small cell lung cancer, breast cancer, recurrent metastatic breast cancer, hepatocellular carcinoma, hodgkin's lymphoma, follicular lymphoma, non-hodgkin's lymphoma, advanced B-cell NHL, HL including diffuse large B-cell lymphoma (DLBCL), multiple myeloma, chronic myeloid leukemia, adult acute myeloid leukemia in remission; adult acute myeloid leukemia with Inv(16)(pl3.1q22); CBFB-MYH11; adult acute myeloid leukemia with t(16;16)(pl3.1;q22); CBFB-MYH11; adult acute myeloid leukemia with t(8;21)(q22;q22);
RUNX1-RUNX1T1; adult acute myeloid leukemia with t(9;l l)(p22;q23); MLLT3-MLL; adult acute promyelocytic leukemia with t(15;17)(q22;ql2); PML-RARA; alkylating agent-related acute myeloid leukemia, chronic lymphocytic leukemia, richter's syndrome; Waldenstrom macroglobulinemia, adult glioblastoma; adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent Ewing sarcoma/ peripheral primitive neuroectodermal tumor, recurrent neuroblastoma; recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer; MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma; recurrent nasopharyngeal undifferentiated carcinoma, cervical adenocarcinoma; cervical adenosquamous carcinoma; cervical squamous cell carcinoma; recurrent cervical carcinoma; stage IVA cervical cancer; stage IVB cervical cancer, anal canal squamous cell carcinoma;
metastatic anal canal carcinoma; recurrent anal canal carcinoma, recurrent head and neck cancer; carcinoma, squamous cell of head and neck, head and neck squamous cell carcinoma (HNSCC), ovarian carcinoma, colon cancer, gastric cancer, advanced GI cancer, gastric adenocarcinoma; gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma; bone sarcoma, thymic carcinoma, urothelial carcinoma, recurrent merkel cell carcinoma; stage III merkel cell carcinoma; stage IV merkel cell carcinoma, myelodysplastic syndrome and recurrent mycosis fungoides and Sezary syndrome.
[0095] In some embodiments, cancers that can be treated with the present invention include ovarian cancer, colon cancer, melanoma, breast cancer or lung cancer.
[0096] It is contemplated that the methods herein reduce tumor size or tumor burden in the subject, and/or reduce metastasis in the subject. In various embodiments, the methods reduce the tumor size by 10%, 20%, 30% or more. In various embodiments, the methods reduce tumor size by 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0097] It is contemplated that the methods herein reduce tumor burden, and also reduce or prevent the recurrence of tumors once the cancer has gone into remission.
[0098] In various embodiments, the STAV or STAV compositions described herein modulates immune cells in a tumor. In some embodiments, the STAV or STAV compositions increases the number of macrophages or other phagocytes or antigen presenting cells in a tumor and/or increases phagocytic activity of cells in the area of the tumor.
[0099] Other conditions or disorders contemplated for treatment with a STAV as described herein include infectious diseases or autoimmune disease in which an increase in immune response may be desired. Exemplary conditions include, but are not limited to, an inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), a peripheral vascular disease, a cerebral vascular accident (stroke), a disorder characterized by lesions having inflammatory cell infiltration, a disorder where amyloid plaques are present in the brain (e.g., Alzheimer's disease), Aicardi-Goutieres syndrome, juvenile arthritis, osteoporosis, amyotrophic lateral sclerosis, or multiple sclerosis.
[00100] Exemplary microbial infections contemplated include viral, bacterial or fungal infection.
Methods of Administration
[00101] Many methods may be used to administer or introduce the dsDNA STAVs or vectors, vaccines or viral particles comprising the dsDNA into individuals (i.e., including subjects or patients), including but not limited to, intratumorally, intravenously, intra-arterially,
intraperitoneally, intranasally, intramuscularly, intradermally, subcutaneously, orally or by continuous infusion. The individual to which a vector or viral particle is administered is a primate, or in other examples, a mammal, or in other examples, a human, but can also be a non- human mammal including but not limited to cows, horses, sheep, pigs, fowl, cats, dogs, hamsters, mice and rats. In the use of a vector, vaccines or viral particles, the individual can be any animal in which a vector or virus is capable introducing the dsDNA and results in activation of STING.
[0100] The present invention encompasses compositions comprising dsDNA, vectors, vaccines or viral particles wherein said compositions can further comprise a pharmaceutically acceptable carrier. The amount of vector(s) to be administered will depend on several factors,
such as route of administration, the condition of the individual, the degree of aggressiveness of the malignancy, and the particular vector employed. Also, the vector may be used in conjunction with other treatment modalities.
[0101] If administered as a viral vector(s), vaccines or viral particles from about 10 up to about 107 p.f .u., in other examples, from about 103 up to about 106 p.f.u., and in other examples, from about 104 up to about 105 p.f.u. is administered. If administered as a polynucleotide construct (i.e., not packaged as a virus), about 0.01 μg to about 100 μg of a viral construct of the present invention can be administered, in other examples, 0.1 μg to about 500 μg, and in other examples, about 0.5 μg to about 200 μg can be administered. More than one vector can be administered, either simultaneously or sequentially. Administrations are typically given periodically, while monitoring any response. Administration can be given, for example, intramuscularly, intravenously, intratumorally or intraperitoneally.
[0102] It is contemplated that an effective amount of the dsDNA, vector(s), vaccines or viral particles is administered. An "effective amount" is an amount sufficient to achieve a desired biological effect such as to induce enough humoral or cellular immunity. This may be dependent upon the type of vaccine, the age, sex, health, and weight of the recipient. Examples of desired biological effects include, but are not limited to, increase in immune response, increase in STING stimulation, decrease in tumor size or tumor burden, production of no symptoms or reduction in symptoms related to disease or condition being treated.
[0103] A vaccine or composition of the present invention is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient that enhances at least one primary or secondary humoral or cellular immune response against a tumor or other targeted cell or microbe. For example, in certain embodiments, the STING activator increases infiltration of immune cells into the tumor or site of infection. In certain embodiments, the immune cells are macrophages, dendritic cells or other phaogcytes.
[0104] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents or pH buffering agents. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
[0105] Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a
hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.
[0106] Pharmaceutical compositions of the present disclosure containing the inhibitors described herein as an active ingredient may contain pharmaceutically acceptable carriers or additives depending on the route of administration. Examples of such carriers or additives include water, a pharmaceutical acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, gelatin, agar, diglycerin, glycerin, propylene glycol, polyethylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like. Additives used are chosen from, but not limited to, the above or combinations thereof, as appropriate, depending on the dosage form of the present disclosure.
[0107] Formulation of the pharmaceutical composition will vary according to the route of administration selected (e.g., solution, emulsion). An appropriate composition comprising the inhibitor, e.g., an antibody, to be administered can be prepared in a physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers.
[0108] A variety of aqueous carriers, e.g., sterile phosphate buffered saline solutions, bacteriostatic water, water, buffered water, 0.4% saline, 0.3% glycine, and the like, and may include other proteins for enhanced stability, such as albumin, lipoprotein, globulin, etc., subjected to mild chemical modifications or the like.
[0109] Therapeutic formulations of the inhibitors are prepared for storage by mixing the inhibitor having the desired degree of purity with optional physiologically acceptable carriers,
excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
(1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn- protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).
[0110] The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
[0111] The active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example,
hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0112] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
[0113] The dose of vector, vaccine or viral particle to be employed in the formulation will also depend on the route of administration, and the nature of the patient, and should be decided according to the judgment of the practitioner and each patient's circumstances according to
standard clinical techniques. The exact amount of vector or virus utilized in a given preparation is not critical provided that the minimum amount of virus necessary to produce immunologic activity is given. A dosage range of as little as about 10 mg, up to amount a milligram or more, is contemplated.
[0114] Effective doses of the vector or viral particle of the invention may also be extrapolated from dose-response curves derived from animal model test systems.
[0115] In one embodiment, administration is performed at the site of a cancer or affected tissue needing treatment by direct injection into the site or via a sustained delivery or sustained release mechanism, which can deliver the formulation internally. For example, biodegradable microspheres or capsules or other biodegradable polymer configurations capable of sustained delivery of a composition (e.g., a soluble polypeptide, antibody, or small molecule) can be included in the formulations of the disclosure implanted near or at site of the cancer.
[0116] Therapeutic compositions may also be delivered to the patient at multiple sites. The multiple administrations may be rendered simultaneously or may be administered over a period of time. In certain cases it is beneficial to provide a continuous flow of the therapeutic composition. Additional therapy may be administered on a period basis, for example, hourly, daily, every other day, twice weekly, three times weekly, weekly, every 2 weeks, every 3 weeks, monthly, or at a longer interval.
Combination Therapy
[0117] It is contemplated that a STAV of the present disclosure or composition thereof is administered with a second agent useful for treating a condition or disorder for which STAV therapy is used, e.g., cancer, infection or autoimmune disease.
[0118] Concurrent administration of two therapeutic agents does not require that the agents be administered at the same time or by the same route, as long as there is an overlap in the time period during which the agents are exerting their therapeutic effect. Simultaneous or sequential administration is contemplated, as is administration on different days or weeks.
[0119] The second agent may be other therapeutic agents, such as cytokines, growth factors, other inhibitors and antibodies to target antigens useful for treating cancer or immunological disorders, for example ipilimumab (YERVOY®, Bristol-Myers Squibb Company), an antibody to
CTLA-4; bevacizumab (AVASTIN®, Genentech), an antibody to VEGF-A; erlotinib (TARCEVA®, Genentech and OSI Pharmaceuticals), a tyrosine kinase inhibitor which acts on EGFR, dasatinib (SPRYCEL®, Bristol-Myers Squibb Company), an oral Bcr-Abl tyrosone kinase inhibitor; IL-21; pegylated IFN-oc2b; axitinib (INLYTA®, Pfizer, Inc.), a tyrosine kinase inhibitor; and trametinib (MEKINIST®, GlaxoSmithKline), a MEK inhibitor (Philips and Atkins, Int Immunol., 27(l):39-46 (2015) which is incorporated herein by reference).
[0120] It is contemplated the STAVs of the present disclosure and second agent may be given simultaneously, in the same formulation. It is further contemplated that the STAV and second agent are administered in a separate formulation and administered concurrently, with
concurrently referring to agents given within 30 minutes of each other. It is further contemplated that the third agent may be given simultaneously with the inhibitors.
[0121] In another aspect, a STAV is administered prior to administration of the second agent. Prior administration refers to administration of a STAV within the range of one week prior to treatment with the second agent, up to 30 minutes before administration of the second agent. It is further contemplated that a STAV is administered subsequent to administration a second agent. Subsequent administration is meant to describe administration from 30 minutes after STAV treatment up to one week after STAV administration.
[0122] It is further contemplated that other adjunct therapies may be administered, where appropriate. For example, the patient may also be administered surgical therapy, chemotherapy, a cytotoxic agent, photodynamic therapy or radiation therapy where appropriate.
[0123] It is further contemplated that when the STAVs herein are administered in combination with a second agent, such as for example, wherein the second agent is a cytokine or growth factor, or a chemotherapeutic agent, the administration also includes use of a radiotherapeutic agent or radiation therapy. The radiation therapy administered in combination with an antibody composition is administered as determined by the treating physician, and at doses typically given to patients being treated for cancer.
[0124] A cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g., 1131, 1125, Y90 and Rel86), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin or synthetic toxins, or fragments thereof. A
non-cytotoxic agent refers to a substance that does not inhibit or prevent the function of cells and/or does not cause destruction of cells. A non-cytotoxic agent may include an agent that can be activated to be cytotoxic. A non-cytotoxic agent may include a bead, liposome, matrix or particle (see, e.g., U.S. Patent Publications 2003/0028071 and 2003/0032995 which are incorporated by reference herein). Such agents may be conjugated, coupled, linked or associated with an antibody according to the disclosure.
[0125] Chemotherapeutic agents contemplated for use with the antibodies of the present disclosure include, but are not limited to those listed in Table I:
Table I
Kits
[0126] As an additional aspect, the disclosure includes kits which comprise one or more compounds or compositions packaged in a manner which facilitates their use to practice methods of the disclosure. In one embodiment, such a kit includes a compound or composition described herein (e.g., a composition comprising a target- specific antibody alone or in combination with another antibody or a third agent), packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition in practicing the method. Preferably, the compound or composition is packaged in a unit dosage form. The kit may further include a device suitable for administering the
composition according to a specific route of administration or for practicing a screening assay. Preferably, the kit contains a label that describes use of the inhibitor compositions.
[0127] Additional aspects and details of the disclosure will be apparent from the following examples, which are intended to be illustrative rather than limiting.
Example 1
[0128] To further investigate the importance of STING in facilitating adaptive immune responses a variety of DNA-dependent nucleic acids were generated and their ability to activate STING signaling was examined.
[0129] Methods
[0130] Mice. STING knockout mice (SKO) were generated as described previously
(Ishikawa and Barber, Nature 455:674-8, 2008) and have been backcrossed with C57BL/6J. Wild type C57BL/6J mice (WT) were provided from Jackson Laboratory. cGAS Knockout mice
(cGAS KO) were kindly provided by Dr. Herbert W. Virgin IV (Washington University School of Medicine). TLR9 Knockout mice (TLR9KO) were purchased from Jackson Laboratory.
Mice care and study were conducted under approval from the Institutional Animal Care and Use Committee of the University of Miami. Mouse genotypes from tail biopsies were determined by using real-time PCR with specific probes designed for each gene by commercial vendor
(Transnetyx).
[0131] Cells. B 16-OVA cells (B 16) were kindly provided by Dr. Eli Gilboa (University of Miami) and cultured in complete Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) including 10% heat-inactivated fetal calf serum (FCS, Invitrogen). 293, 293T cells and hTERT cells were purchased from ATCC. Mouse embryonic fibroblasts (MEFs) were obtained from el 3.5 embryos by a standard procedure. Bone marrow derived macrophages (BMDM; ΜΦ) were isolated from hind-limb femurs of 8-10 weeks old WT, SKO, cGASKO, TLR9KO, DNase IKO, DNase II KO, or DNase III (Trexl) KO mice. Briefly, the marrow cells were flushed from the bones with complete DMEM with a 26 gauge needle. The cells were cultured in complete DMEM (Invitrogen) including 10 ng/ml of Mouse Recombinant Colony-Stimulating Factor (M- CSF, R&D Systems,) for 10 to 14 days.
[0132] STING-dependent, TLR9-independent adjuvants (STAVs). A ssDNA sense strand modified with Phosphorothioates (S-oligos) at the end (polyA90mer) was annealed to ssDNA antisense strand with same modification as anti-sense strand (polyT90mer); STAVs. Each oligos were synthesized and modified from TriLink Biotechnologies.
[0133] In vitro phagocytosis. ΜΦ was cultured as described above and seeded on 12 well plates (2xl05 cells/well). B 16-OVA cells were transfected with STAVs at 3 ug/ml for 3 hours and irradiated by a UVC500 UV crosslinker at 120 mJ/cm followed by 24 hour incubation. The treated B 16-OVA cells were added to macrophages for 6 hours. Following vigorous washing to remove unengulfed B 16-OVA cells, the macrophages were harvested for RNA extraction for qPCR and Gene array analysis. To check phagocytosis efficiency, macrophages were collected at 4 hours after phagocytosis and stained using APC-anti-mouse CD1 lb antibody (eBiosciences). Percentage of phagocytosed cells was assessed by flow cytometry using a LSRII instrument (Becton Dickinson, USA).
[0134] Gene Array Analysis. Total RNA was isolated from cells or tissues with RNeasy Mini kit (Qiagen). RNA quality was analyzed by Bionalyzer RNA 6000 Nano (Agilent
Technologies). Gene array analysis was examined by Affymetrix Mouse Gene array (2.0 ST Array) at Hussman Institute for Human Genomics University of Miami. Gene expression profiles were processed and statistical analysis was performed at Public health science,
University of Miami.
[0135] Quantitative Real-Time PCR (qPCR). Total RNA was extracted from cells using Trizol method and reverse transcribed by M-MLV reverse transcriptase (Promega). Real-time PCR was performed with the TaqMan gene Expression Assay (Ifn-β: Mm010439546, CxcllO : Mm00445235 ; Applied Biosystems).
[0136] Cell death induction and analysis. B 16-OVA cells were transfected with 3μg/mL STAVs for 3 hours and then were treated by UV light (120 mJ/cm2). After 24 hours at 37°C, 5% C02, cells were collected and fed to bone marrow-derived macrophages for 6 hours. B 16-OVA cells viability was assessed by flow cytometric analysis with a FACSCantoII (Becton Dickinson, USA) after staining with 1 μg/mL propidium iodide (eBiosciences) and APC-labeled annexin V (eBiosciences).
[0137] Transfection efficiency. STAVs transfection efficiency into B 16-OVA or 293T cells was evaluated by flow cytometry analysis. The cells were transfected with 3 μg/mL of FAM- labeled STAVs. After 24 hours, cells were collected and analyzed by flow cytometry using a LSRII instrument (Becton Dickinson, USA).
[0138] Antigen presentation assay. Bone marrow-derived macrophages were transfected with 3 μg/mL of STAVs for 24 hours and then pulsed with or without SIINFEKL (3 μΜ). After 2 hours, cells were stained with APC-labeled anti-H-2Kb-SIINFEKL (clone 25-D1.16)
(Biologend) and FITC-labeled anti-mouse CDl lb (eBiosciences). Presentation of SIINFEKL on H-2Kb was evaluated by flow cytometry using a LSRII instrument (Becton Dickinson, USA).
[0139] Immunofluorescence staining. Cells were fixed with 4% paraformaldehyde in DMEM for 15 min at 37°C and were permeabilized with 0.2% Triton X-100. Fixed and permeabilized cells were blocked with 10% BSA in PBS, incubated with primary antibodies in 2% BSA in PBS and then incubated with fluorophore-conjugated secondary antibodies (with Dapi
counters taining). After staining, cells were mounted in anti-fade mounting solution (Invitrogen) and examined under Leica SP5 spectral confocal inverted microscope.
[0140] Mass spectrometry analysis. The cells were transfected with 3 μg/mL of STAVs for 3 hrs or 1 μg/mL of pCMV or pcGAS plasmids for 24 hours. Following appropriate treatment, 1x10' cells were pelleted and snap-frozen in liquid nitrogen and stored at -80 °C before further processing. To extract cGAMP, frozen cells were thawed on ice and lysed in cold 80% (vol/vol) methanol with 2% (vol/vol) acetic acid (HAc). Cyclic-di-GMP was supplemented as internal standard. Cell lysates were cleared by centrifugation at 4 °C, 10,000 x g for 10 min. Pellets were further extracted in 20% (vol/vol) methanol with 2% HAc twice and all extracts were pooled. cGAMP was then enriched by solid-phase extraction (SPE) using HyperSep Aminopropyl SPE Columns (Thermo Scientific) as previously described in Gao et al, 2015. Briefly, columns were activated by 100% methanol and washed twice with 2% HAc; after drawing through the extracts, columns were washed twice with 2% HAc and once with 80% methanol, and finally eluted with 2% (vol/vol) ammonium hydroxide in 80% methanol. The eluents were spin-vacuumed to dryness, reconstituted in liquid chromatography (LC)/MS -grade water and stored at -20 °C before subject to LC/MS analysis. Chromatography was performed using a Thermo Scientific Surveyor MS Pump Plus pump and Micro AS autosampler. The separation was isocratic on a Water's XBridge Amide column (3.5 urn, 2.1x100 mm) at 200 ul/min using 18:82
water: acetonitrile 6.3 mM ammonium hydroxide and 6.3 mM ammonium bicarbonate. The samples were introduced into a Thermo Scientific LTQ-FT, a hybrid mass spectrometer consisting of a linear ion trap and a Fourier transform ion cyclotron resonance mass
spectrometer. The standard electrospray source was used operated in negative ion mode.
cGAMP was quantitated using the m/z 522 product ion from the collision-induced dissociation of the deprotonated parent ion at m/z 673. An external calibration curve derived from eight standards [you can elaborate on the standards preparation if you wish] was used in the quantitation and acquired before and after the samples were analyzed. The c-di-GMP component was quantitated from the m/z 344 product ion originating from the deprotonated m/z 689 parent.
[0141] In vivo models. For anti-tumor effects, mice were subcutaneously injected with 5xl05 cells of B 16-OVA on the right flank. One week later, when tumors were 50mm in volume, 10 μg of STAVs was injected intratumorally (i.t.) every three days 3 times. The tumor volume was measured using calipers and calculated with the formula V=(length x width )/2. For post-
vaccination in tumor bearing mice, mice were intravenously (i.v.) injected with B 16 OVA cells (1 x 105 cells / mouse). At 1, 3, 7, and 14 days, mice were injected intraperitoneally (i.p.) with UV irradiated B 16 OVA cells (1 x 106 cells / mouse). Survival rates were monitored for 110 days. B 16-OVA cells were transfected with STAV at 3 μg/ml for 3 hours and irradiated by a UVC500 UV crosslinker at 120 mJ/cm followed by 24 hours incubation.
[0142] OVA specific CD8+ T cell analysis and IFN yELISA. 1-2 x 106 splenocytes were stained with H-2Kb/SIINFEKL Pro5® Pentamer (Prolmmune, UK) for 10 minutes at 22°C. Cells were then washed twice and incubated with FITC-labeled anti-mouse CD8 (eBiosciences) and PECy5-labeled anti-mouse CD19 (Prolmmune, UK) antibodies for 20 minutes on ice, shielded from light. Following two further washes, cells were resuspended in fixative and analyzed by flow cytometry using a LSRII instrument (Becton Dickinson, USA). For IFNP ELISA, 1 x 106 splenocytes were plated and stimulated with SIINFEKEL peptide (10 μg/ml). At 2 days after stimulation, the supernatant was harvested and IFNP production was estimated by BD mouse IFNp kit.
[0143] Statistical Analysis. All statistical analysis was performed by Student's t test. The data were considered to be significantly different when P < 0.05.
[0144] Results
[0145] To further investigate the importance of STING in facilitating adaptive immune responses a variety of DNA-dependent nucleic acids were generated and examined for their ability to activate STING signaling. It was noted that transfected cytosolic dsDNA's, modified on the 5'end to help prevent exonuclease degradation, greater than approximately 30 bp in murine cells (MEFs; murine embryonic fibroblasts) or 70 bp in human cells (hTERT and primary human macrophages) were required for the efficient activation of STING (Fig. 1A-I). The effects, following transfection appeared to be largely independent of sequence specificity and both AT or GC rich structures were readily able to trigger STING activity. As a result of these endeavors, an AT rich STING activating dsDNA ligand of 90 bp with modified 5'-ends (referred to as STAV) was used for further study. Following the transfection of a variety of cells including murine B 16 cells, it was observed that the majority of the STAVs remained in the cytosol of the cell in as yet undefined cellular compartments (Figure 2A). Quantitation studies
indicated that the cytosolic STAVs constituted approximately 1% of the total cellular DNA content as determined by quantitation analysis (Figure 1J).
[0146] To evaluate the importance of STING signaling in the stimulation of APC's following cellular engulfment, B 16 cells were transfected with STAVs, routinely obtaining greater than 90% transfection efficiency (Figure 2A) and it was confirmed that B 16 cells exhibited cytosolic DNA-dependent STING signaling as determined by observing an increase in cytokine production, including CxcllO (Figures 2B-E and Figure 11). This was performed since it was previously noted that numerous types of cancer cells appear defective in STING signaling, perhaps to avoid DNA-damage mediated cytokine production that can occur via intrinsic STING signaling, which likely alerts the immune system to the vicinity of the damaged cell (Xia et al., Cell Rep 14:282-297, 2016; Xia et al., Cancer Res., 76:6747-6759, 2016). STAV containing cells were then UV treated, which triggered the apoptosis of greater than 90% within 24 hours, and the cells fed to phagocytes (murine bone marrow derived macrophages) in vitro (Figure 2F), and 90% of the STAVs remained in the treated cells (Figure 3A-B). Approximately 50% of the macrophages consistently engulfed the cells as determined using B 16 cells transfected with fluorescently labeled STAVs (Figure 2F-H, Figure 3C). UV treated B 16 cells alone or B 16 cells containing Poly I:C failed to stimulate the macrophages as verified by measuring CxcllO, type I IFN, macrophage maturation marker (CD86) and MHI class I (H2kD) (Figure 2I-L, Figure 3D). However, B 16 cells containing STAVs robustly induced the production of cytokines in macrophages that was dependent on extrinsic STING signaling within the macrophage (Figure 2I-L). A similar effect was observed following the phagocytosis of HEK293 cells containing STAVs (Figure 4 and Figure 12). This data indicated that exogenous cytosolic DNA species present in engulfed apoptotic cells, but not apoptotic cells alone can potently stimulate the activation of macrophages in trans.
[0147] It is possible that the transfected cytosolic DNA could stimulate intrinsic STING signaling within the treated cell and facilitate the production of immunoregulatory cytokines that may provoke APC activation. To thus evaluate whether STING acts extrinsically or intrinsically within the engulfed cell itself, mouse embryonic fibroblasts (MEFs) that lacked STING or cGAS were treated with STAVs and confirmed that both STING and cGAS were required to produce cytokines such as type I IFN in the presence of cytosolic DNA (Figures 5A and 5B). UV treated MEFs were then incubated with macrophages to ascertain the latter' s activation (Figure
5C). The results again indicated that only apoptotic cells containing cytosolic DNA were able to activate macrophages (Figures 5D-5E). Indeed, MEFs lacking cGAS or STING, transfected with STAVs remained able to activate APCs, indicating that STING-dependent cytokine production within the engulfed cell was not completely essential for macrophage activation in vitro (Figures 5A, 5D, and 5E). This data suggests that exogenous cytosolic DNA but not endogenous cellular DNA, is responsible for the stimulation of the APCs including macrophages. To complement these studies STAVs were transfected into human 293T cells that lack both cGAS and STING. Unlike normal human hTERT cells, 293T cells are consequently unable to produce type I IFN in response to STAVs (Figure 5F). STAVs-treated 293T cells were then incubated with murine macrophages and observed that only 293T cells containing STAVs were able to stimulate cytokine production in engulfing macrophages (Figure 5G-5H). This effect was dependent on STING signaling in the macrophages (Figure 5G-5H). Since neither cGAS nor STING are present within the 293T cell, the stimulation of engulfing macrophages can presumably directly occur in trans by cytosolic DNA (STAVs) promoting STING signaling in APCs (i.e., macrophages).
[0148] It is accepted in the field that the nuclear DNA, and plausibly mitochondrial DNA, undergoes degradation during the apoptotic process. The responsible nucleases within the nuclei include CAD (caspase activated DNAse), which cleaves the genomic DNA between
nucleosomes (14, 19). Thus, fragments of nuclear DNA sufficient to activate STING may not be generated, nor escape into the cytosol to activate STING signaling.
[0149] In view of this, the importance of STING signaling for activation within in the engulfing APC, and the importance of extrinsic STING signaling, was examined. To accomplish this B 16 cells were treated with STAVs and fed to murine macrophages lacking STING or cGAS. This analysis surprisingly indicted that macrophages lacking cGAS or TLR9, but not
STING, were readily able to be activated by cells containing STAVs (Figure 6A). Thus,
STING, but not cGAS, is essential for the activation of APCs following cellular engulfment.
This event did not require TLR9. However, cGAS itself was also not required for this process suggesting that STAVs within the UV treated cell could be binding to an alternate DNA binding,
STING-activating molecule in the APCs or conversely that CDNs were being generated with the
B 16 cell by cGAS and these ligands are able to activate STING extrinsically within the APC, in trans. To evaluate this, it was confirmed that cGAS was expressed in B 16 cells and mass
spectrometry showed that STAV treated, but not untreated B 16 cells, produced CDNs (Figure 6B) and can likely also act in trans.
[0150] To further confirm this, 293T cells that lack cGAS or STING were transfected with STAVs. Unlike B 16 or MEF cells, these cells cannot generate CDNs. It was confirmed that STAV-containing 293T cells were able to modestly stimulate control macrophages, but not macrophages that lacked STING (Figure 6C). It was also observed that macrophages lacking cGAS were similarly unable to be activated by 293T cells containing STAVs, since the STAVs are probably unable to activate cGAS -generated CDNs production within the APC to activate STING (Figure 6C). To explore this further, 293T cells were reconstituted with a plasmid expressing cGAS. Data shows that 293T cells expressing cGAS could readily generate CDN's, as determined by mass spectrometry and that these CDN containing cells could significantly activate macrophages in a STING-dependent manner, compared to cytosolic DNA (STAVs) alone (Figure 6C). The cGAS re-constituted 293T cells could activate macrophages lacking cGAS itself, since the 293T generated CDNs could almost certainly act directly on STING
(Figure 6C-D). These effects were confirmed using a human colon cancer cell-line that similarly lacks cGAS (HT116) (Figure 6E). In addition, the data indicated that the DNA virus HSV1 (γ34.5) also functioned similarly to the STAVs following infection of B 16 cells. That is, only engulfed viral-infected cells and not uninfected cells, could activate macrophages. Further, this event occurred in a similar cGAS/STING-dependent manner (Figure 6F).
[0151] The results suggest that STAVs transfected into cells can extrinsically activate the cGAS/STING axis in macrophages. Second, STAVs can generate CDNs within the treated cell which can also act in trans to stimulate extrinsic STING signaling in APCs. Further, reconstitution of cGAS, for example within a tumor cell, can generate CDNs which are able to similarly act in trans to stimulate the activation of macrophages via STING. Finally, host macrophages can distinguish between a viral infected and uninfected dying cell predominantly through cGAS/STING detection of viral cytoplasmic DNA, analogous to STAVs.
[0152] Given that CDNs generated within a cell exhibit considerable ability to stimulate macrophages in trans, CDNs were directly transfected into B 16 and 293T cells and the cells fed to macrophages. This analysis indicated that tumor cells containing exogenously added CDN's were readily engulfed by macrophages, but were not potent activators of STING signaling in
trans or of macrophage activation (Figure 5). This is in contrast to when the cGAS was transfected within the tumor cell to generate endogenous CDNs. In contrast, the direct transfection of CDNs or indeed STAVs into APCs were readily able to induce their activation and to enhance the cross presentation of antigen in a STING specific manner (Figure 7). The present results indicate that exogenously added CDN's do not appear to exert their anti-tumor effect by working on the cancer cell itself but more likely function by directly stimulating the APC to facilitate STING-dependent cytokine induced antigen cross-presentation following cellular engulfment.
[0153] The present data thus indicates that cytosolic DNA (STAVs) or CDNs can activate APCs directly or indirectly and facilitate antigen cross-presentation. It remained unclear why cytosolic DNA (STAVs) and not cellular DNA was able to stimulate APCs in trans. Nuclear DNA, and plausibly mitochondrial DNA, undergoes degradation during the apoptotic process. The responsible nucleases within the nuclei which cleaves genomic DNA between nucleosomes involves CAD (caspase activated DNAse) (14, 21). Thus, fragments of nuclear DNA sufficient to activate STING signaling may not be generated, nor escape into the cytosol. Following engulfment by macrophages, the remainder of the DNA is degraded by additional DNases such as DNasell within the lysosomal compartment of APCs (13, 18). It is thus plausible that cytosolic DNA species (STAVs/viral DNA) escape cellular degradation within the apoptotic cell and following engulfment in APCs is more readily available the lysosomal compartment and stimulate extrinsic cGAS-STING signaling in the APC. To explore this further, macrophages from mice lacking DNase I (Figure 8B), II (Figure 8B), or III (Trexl) (Figure 8D) were retrieved and fed B 16 cells containing or lacking STAVs. The data again indicated that apoptotic cells poorly activate normal macrophages, perhaps explaining why tumor cells are generally non- immunogenic. However, APCs lacking DNase II, but not DNase I or DNase III exhibited an increase in cytokine production following engulfment of untreated apoptotic cells (Figure 8). This event was greatly augmented in STAVs containing cells (Figure 8).
[0154] This data confirms that DNases such as CAD efficiently degrade self-DNA within apoptotic cells to help prevent the activation of macrophages. In addition, DNasell in APCs predominantly ensures that any engulfed apoptotic DNA that escapes degradation is broken down in lysosomal compartments into non-STING activating nucleotides. Interestingly, cells containing cytosolic DNA (STAVs) or cytoplasmic viral DNA likely escape degradation in the
dying cell and are able to stimulate extrinsic cGAS/STING signaling, prior to degradation of by DNasell. Thus, CDN's as DAMPs may better avoid degradation following engulfment and enable a phagocyte to determined that the cell has been infected or undergone DNA damage, and become activated.
[0155] The data herein suggests that cells have devised efficient ways to eliminate the lethal possibility of self-DNA activating innate immune sensor pathways such as those governed by STING (18, 22). Likely, tumor cells also utilize this process to remain immunologically indolent. To determine whether STAVs could render tumor cells immunogenic in vivo, B 16-OVA melanoma cells containing or lacking STAVs were intratumorally inoculated into
immunocompetent C57BL/6J mice (Figure 9A). It was observed that B 16-OVA cells treated with STAVs exhibited less growth compared to mice inoculated with untreated cells (Figure 9B). In addition, the STAVs containing cells did not exert any anti-tumor activity in the absence of STING in the recipient mice (Figure 9C). The ability of the STAVs to inhibit tumor growth involved the generation of anti-tumor CTLs to the tumor, as determined by measuring anti- SIINFEKL specific CD8 T cells (Figure 9D). This data would indicate that tumor cells containing STAVs could be potent stimulators of anti-tumor immunity.
[0156] To further evaluate whether STAV containing cells were able to generate immune responses in murine models, B 16-OVA cells were loaded with STAVs and irradiated and used to immunize B6 mice (Figure 10A). This study indicated that STAVs containing cells were competent to generate type II IFN, an indicator of CTL generation (Figure 10B). STAV dependent type II IFN production was dependent on STING and cGAS, but not TLR9. This data would indicate that tumor cells containing STAVs could be potent stimulators of anti-tumor immunity. To examine this, C57BL/6 mice were inoculated intravenously with B 16-OVA melanoma cells to indue tumors and subsequently post-vaccinated with B 16-OVA cells loaded with STAVs (Figure IOC). Results showed that the B 16 OVA tumors killed the majority of mice within 40 days (Figure 10D). However, mice treated with B 16-OVA STAVs had a median half-life of 70 days, with 40% of the mice alive after 100 days (Figure 10D). Mice lacking STING (Figure 10E) or cGAS (Figure 10F), but not TLR9 (Figure 10G), however, succumbed to lethal disease similar to wild type mice, indicating the importance of STING signaling in combatting cancer development. Thus, cells containing STAVs may provide an effective treatment for the prevention of cancer.
[0157] Collectively, the results indicate that cytosolic dsDNA species present within a dying cell can activate extrinsic STING signaling in phagocytes likely following association with cGAS which would generate CDNs. It is likely that the cytosolic DNA species avoid being degraded by nuclear DNAses, responsible for degrading genomic DNA. Such cytosolic species appear significantly more capable of activating STING in phagocytes, likely as a result of avoiding being degraded within the apoptotic cell. DNAse resistant cytosolic species were thus more competent at activating STING in trans. In addition, CDNs generated from an infected or damaged cell are able to directly activate STING-dependent signaling in APC's in trans to trigger inflammatory responses, the cross-presentation of antigen and the spontaneous generation of T cells. CDN's generated within a dying cell are also predominantly resistant to the activity of DNAses within the engulfed phagocyte, unlike susceptible cellular DNA, which makes them highly efficient at stimulating extrinsic STING signaling. It is likely that tumorigenic cells closely mimic normal cells undergoing apoptosis and avoid triggering STING signaling. Thus, tumorigenic cells are predominantly non-immunogenic. It is hypothesized that intrinsic STING signaling is likely important within a dying/infected cell to alert APC's to the damaged region, while the extrinsic STING signaling component within macrophages is critical for the production of cytokines such as Type I interferon that facilitate cross presentation events.
[0158] The data indicates that numerous tumor cells exhibit defective STING signaling. This would presumably enable the damaged cell to avoid alerting the immune system for removal and for antigen presentation. However, the data also indicates that by suppressing pathogen or DNA damaged driven CDN generation, an engulfed cell would also avoid the activation of the APC itself. This may help explain why the STING/cGAS pathway is so commonly deregulated in certain cancers. The results further indicate that reconstitution of CDN's and STING signaling may not only alert the immune system to the damaged/infected/tumor cell, but also potently trigger cytokine production, inflammatory responses, antigen cross-presentation and spontaneous T cell generation. The use of STAVs to treat cancer, either directly into tumors, or carried inside tumor cells, or as vaccine adjuvants may provide powerful new anti-tumor therapies. Moreover, the generation of CDNs within a tumor cell may also provide a powerful approach to stimulate the anti-tumor T cell responses. Finally, the data provides an explanation for how phagocytes are able to avoid being activated following the engulfment of generally apoptotic cells versus a DNA damaged or infected cell, which contains DAMPs in the form of CDNs.
[0159] Numerous modifications and variations in the invention as set forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.
References
1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10): 1014-22.
2. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405-14.
3. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10): 1989-2003.
4. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208(10):2005-16.
5. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Drain N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L, Kroemer G. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729-41.
6. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, Bureau F, Desmet CJ. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011;17(8):996-1002.
7. Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol.
2015;15(12):760-70.
8. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity.
2014;41(5):830-42.
9. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR,
Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW, Jr., Gajewski TF. Direct
Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor
Regression and Immunity. Cell Rep. 2015;11(7): 1018-30.
10. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41(5):843-52.
11. Ablasser A, Goldeck M, Caviar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498(7454):380-4.
12. Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014;35(2):88-93.
13. Kawane K, Fukuyama H, Kondoh G, Takeda J, Ohsawa Y, Uchiyama Y, Nagata S. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science.
2001;292(5521): 1546-9.
14. Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ. 2003;10(1): 108-16.
15. Ahn J, Barber GN. Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Curr Opin Immunol. 2014;31: 121-6.
16. Belz GT, Smith CM, Eichner D, Shortman K, Karupiah G, Carbone FR, Heath WR. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol. 2004; 172(4): 1996-2000.
17. Smith CM, Belz GT, Wilson NS, Villadangos JA, Shortman K, Carbone FR, Heath WR. Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol. 2003;170(9):4437-40.
18. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A. 2012;109(47): 19386-91.
19. Mcllroy D, Tanaka M, Sakahira H, Fukuyama H, Suzuki M, Yamamura K, Ohsawa Y, Uchiyama Y, Nagata S. An auxiliary mode of apoptotic DNA fragmentation provided by phagocytes. Genes Dev. 2000;14(5):549-58.
Claims
1. An activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
2. The activator of claim 1 wherein the dsDNA is approximately 30 nucleotides in length.
3. The activator of claim 1 wherein the dsDNA is approximately 70 nucleotides in length.
4. The activator of claim 1 wherein the dsDNA is AT rich or GC rich.
5. The activator of claim 1 wherein the 5' end and/or 3' end is modified by phosphorothioate linkage.
6. The activator of claim 1 wherein the nucleotide is modified at every third base.
7. The activator of any one of the preceding claims wherein the activator has a sequence as follows
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 1) optionally wherein the first three and last three nucleotides are modified by phosphorothioate linkage; or
last three nucleotides are modified by phosphorothioate linkage.
8. A composition comprising a STING activator of any one of claims 1-7 and a pharmaceutically acceptable carrier.
9. A sterile composition comprising a STING activator of any one of claims 1-7.
10. A vector comprising a STING activator comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
11. A vaccine comprising a STING activator comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
12. The vaccine of claim 11 wherein the nucleotide is in a vector.
13. The vaccine of claim 11 wherein the vector is a viral or a plasmid vector.
14. The vaccine of claim 12, wherein the viral vector is selected from the group consisting of vesicular stomatitis virus (VSV), a lentivirus, an acdenovirus, an adeno-associated virus, a vaccinia virus and a modified vaccinia Ankara (MVA) virus.
15. A method of activating STING in a subject in need thereof comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
16. A method of stimulating an immune response in a subject in need thereof comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
17. The method of claim 14 wherein the subject is suffering from cancer or a microbial infection.
18. A method of decreasing the size of a tumor in a subject comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
19. A method of treating cancer in a subject comprising administering a composition comprising an activator of STING (STimulator of INterferon Genes) comprising a double stranded DNA (dsDNA) having a modified 5' end and comprising between 25 and 90 nucleotides, wherein the activator induces STING signaling.
20. The method of claim 19 wherein the cancer is ovarian cancer, colon cancer, melanoma, breast cancer or lung cancer.
21. The method of any one of claims 18 or 20 wherein tumor size in the subject is decreased by about 25-50%, about 40-70% or about 50-90% or more.
22. The method of any one of claims 15-21 wherein the STING activator is administered intratumorally, intravenously, intra-arterially, intraperitoneally, intranasally, intramuscularly, intradermally or subcutaneously.
23. The method of any one of claims 15-22 wherein the STING activator induces infiltration of immune cells into the tumor.
24. The method of claim 23 wherein the immune cells are macrophages or other phagocytes.
25. The method of any one of claims 15-24 wherein the STING activator oligonucleotide remains cytosolic in a cell.
26. The method of any one of claims 15-25 wherein the STING activator induces CxcllO and/or type I IFN cytokine production.
27. The method of any one of claims 15-26 wherein the dsDNA is approximately 30 nucleotides in length.
28. The method of any one of claims 15-26 wherein the dsDNA is approximately 70 nucleotides in length.
29. The method of any one of claims 15-28 wherein the dsDNA is AT rich or GC rich.
30. The method of any one of claims 15-29 wherein the 5' end is modified by.
31. The method of any one of claims 15-30 wherein the nucleotide is modified at every third base.
last three nucleotides are modified by phosphorothioate linkage.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020207001057A KR20200028392A (en) | 2017-06-12 | 2018-06-12 | STING-dependent activator for the treatment of diseases |
US16/621,820 US11629346B2 (en) | 2017-06-12 | 2018-06-12 | Sting-dependent activators for treatment of disease |
EP18817870.1A EP3638252A4 (en) | 2017-06-12 | 2018-06-12 | Sting-dependent activators for treatment of disease |
US18/176,406 US20230241092A1 (en) | 2017-06-12 | 2023-02-28 | Lipid nanoparticles for delivery of sting-dependent adjuvants |
US18/176,396 US20230242913A1 (en) | 2017-06-12 | 2023-02-28 | Sting-dependent activators for treatment of disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762518292P | 2017-06-12 | 2017-06-12 | |
US62/518,292 | 2017-06-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/034796 Continuation-In-Part WO2022271995A1 (en) | 2017-06-12 | 2022-06-23 | Sting dependent adjuvants |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/621,820 A-371-Of-International US11629346B2 (en) | 2017-06-12 | 2018-06-12 | Sting-dependent activators for treatment of disease |
US18/176,406 Continuation-In-Part US20230241092A1 (en) | 2017-06-12 | 2023-02-28 | Lipid nanoparticles for delivery of sting-dependent adjuvants |
US18/176,396 Continuation US20230242913A1 (en) | 2017-06-12 | 2023-02-28 | Sting-dependent activators for treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018231752A1 true WO2018231752A1 (en) | 2018-12-20 |
Family
ID=64659465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/036997 WO2018231752A1 (en) | 2017-06-12 | 2018-06-12 | Sting-dependent activators for treatment of disease |
Country Status (4)
Country | Link |
---|---|
US (2) | US11629346B2 (en) |
EP (1) | EP3638252A4 (en) |
KR (1) | KR20200028392A (en) |
WO (1) | WO2018231752A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022271995A1 (en) * | 2021-06-24 | 2022-12-29 | University Of Miami | Sting dependent adjuvants |
US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023196185A1 (en) * | 2022-04-04 | 2023-10-12 | Spark Therapeutics, Inc. | Immune enhancement and infectious disease treatment |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137139A1 (en) * | 1999-01-12 | 2002-09-26 | Byatt John C | Nucleic acid and other molecules associated with lactation and muscle and fat deposition |
US20160024508A1 (en) * | 2010-12-21 | 2016-01-28 | Index Pharmaceuticals Ab | Method for identifying biologically active oligonucleotides capable of modulating the immune system |
WO2016201450A2 (en) * | 2015-06-11 | 2016-12-15 | University Of Miami | Cancer treatment and diagnosis |
US20170037400A1 (en) * | 2008-08-04 | 2017-02-09 | Glen N. Barber | Modulating immune responses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1944369A1 (en) * | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait and its standalone uses thereof |
US9770467B2 (en) * | 2012-06-08 | 2017-09-26 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
WO2017007027A1 (en) * | 2015-07-09 | 2017-01-12 | 国立研究開発法人物質・材料研究機構 | Immune-stimulating oligonucleotide complex |
-
2018
- 2018-06-12 EP EP18817870.1A patent/EP3638252A4/en active Pending
- 2018-06-12 KR KR1020207001057A patent/KR20200028392A/en unknown
- 2018-06-12 WO PCT/US2018/036997 patent/WO2018231752A1/en unknown
- 2018-06-12 US US16/621,820 patent/US11629346B2/en active Active
-
2023
- 2023-02-28 US US18/176,396 patent/US20230242913A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137139A1 (en) * | 1999-01-12 | 2002-09-26 | Byatt John C | Nucleic acid and other molecules associated with lactation and muscle and fat deposition |
US20170037400A1 (en) * | 2008-08-04 | 2017-02-09 | Glen N. Barber | Modulating immune responses |
US20160024508A1 (en) * | 2010-12-21 | 2016-01-28 | Index Pharmaceuticals Ab | Method for identifying biologically active oligonucleotides capable of modulating the immune system |
WO2016201450A2 (en) * | 2015-06-11 | 2016-12-15 | University Of Miami | Cancer treatment and diagnosis |
Non-Patent Citations (4)
Title |
---|
See also references of EP3638252A4 * |
SUN ET AL.: "ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES , USA, vol. 106, no. 21, 26 May 2009 (2009-05-26), pages 8653 - 8658, XP055021622 * |
YANG ET AL.: "Synthesis and investigation of deoxyribonucleic acid/locked nucleic acid chimeric molecular beacons", NUCLEIC ACIDS RESEARCH, vol. 35, no. 12, 8 June 2007 (2007-06-08), XP008136134 * |
ZHOU ET AL.: "The ER-Associated Protein ZDHHC1 Is a Positive Regulator of DNA Virus-Triggered, MITA/STING-Dependent Innate Immune Signaling", CELL HOST & MICROBE, vol. 16, no. 4, 8 October 2014 (2014-10-08), pages 450 - 461, XP029073138 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2022271995A1 (en) * | 2021-06-24 | 2022-12-29 | University Of Miami | Sting dependent adjuvants |
Also Published As
Publication number | Publication date |
---|---|
EP3638252A4 (en) | 2021-03-10 |
KR20200028392A (en) | 2020-03-16 |
US11629346B2 (en) | 2023-04-18 |
US20230242913A1 (en) | 2023-08-03 |
US20210355490A1 (en) | 2021-11-18 |
EP3638252A1 (en) | 2020-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2768829C2 (en) | Anticancer rna vaccines | |
US20230242913A1 (en) | Sting-dependent activators for treatment of disease | |
JP6678582B2 (en) | Compositions and vaccines, combinations and kits for treating lung cancer | |
JP6885867B2 (en) | Combination tumor immunotherapy | |
US9828601B2 (en) | Compositions for inhibiting checkpoint gene expression and uses thereof | |
Grauer et al. | TLR ligands in the local treatment of established intracerebral murine gliomas | |
EP3269811B1 (en) | Nucleic acid having adjuvant activity and use thereof | |
JP2020530981A (en) | Antisense oligonucleotides for regulating T cell function | |
WO2008086610A1 (en) | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity | |
CN112672748A (en) | RIG-I agonists and treatments using the same | |
US20210030783A1 (en) | Compositions and methods for tumor immunotherapy | |
CN115518073A (en) | Antisense oligonucleotides for treating cancer stem cells | |
US8568976B2 (en) | Proinflammatory nucleic acids | |
WO2020225779A1 (en) | Rig-i agonists for cancer treatment and immunotherapy | |
WO2016071431A9 (en) | A combination for cancer therapy | |
AU2016377398B2 (en) | Nucleic acid oligomers and uses therefor | |
JP2018057364A (en) | Modified cancer cell lines and uses thereof | |
WO2022061112A1 (en) | Combination treatment for cancer | |
JP2023553352A (en) | immunotherapy for cancer | |
WO2023237726A1 (en) | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer | |
CN118265791A (en) | Spherical nucleic acids for cGAS-STING and STAT3 pathway modulation for immunotherapeutic treatment of cancer | |
AU2014203642A1 (en) | HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18817870 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018817870 Country of ref document: EP Effective date: 20200113 |